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DEFINITIONS 
 
Calcium transient                 A brief change in fluorescence intensity induced by     
                                             calcium  entering the cell through a Voltage-Gated     
                                             Calcium Channel  
Cardiac Hypertrophy An adaptive response of the heart to preserve Left 
Ventricular function in physiological or pathological 
states 
Congestive Heart Failure Insufficient cardiac pumping capacity 
EC coupling Exitation-contraction coupling 
Genotype The genetic constitution of a cell, an organism or an 
individual   
Heart failure A complex clinical syndrome that can results from 
any structural of functional disorder that impairs the 
ability of the ventricle to fill or eject blood 
Knock-out The genotype of an organism when one or more genes 
have  been turned off through a targeted mutation. 
Inotropism The force of cardiac contraction 
Transgenic organism Genetically modified organism 
Wildtype  The phenotype of the typical form of a species as it 
occurs in nature  
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ABBREVIATIONS 
 
AA Amino acid 
AbA  Aureobasidin A 
Ad Adenovirus vector 
AID ! interaction domain (L-Type Calcium Channels) 
AF Atrial Fibrillation 
AM Acetoxymethyl 
ATP Adenosine trisphosphate  
#-ARs #-Adrenergic Receptors 
BDM 2,3-butanedione monoxime  
BID # interaction domain (L-Type Calcium Channels)                       
Bp Base pair 
BSA Bovine Albumine Serum 
CA Constitutive active 
Ca2+ Calcium ion 
[Ca2+]i Intracellular calcium concentration 
CaCl2 Calcium Chloride 
cDNA Cyclic DeoxyriboNucleic Acid 
Cs Cesium 
cAMP cyclic Adenosine-Mono-Phosphate 
CHF Congestive Heart Failure 
CMC Cardiomyocytes 
CO-IP Co-immunoprecipitation 
DCM Diabetic Cardiomyopathy 
DHPR Dihydropyridine receptors 
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DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dymetil sulfoxide 
DN Dominant Negative 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribonucleoside triphosphate 
DTT Dithiothreitol 
EC coupling Exitation-contraction coupling 
EDTA Ethylene Diamine Tetraacetic Acid 
EGTA Ethylene Glycol-bis(beta-aminoethyl-ether)-
N,N,N',N'-TetraAcetate 
ER Endoplasmatic reticulum 
FBS Fetal Bovine Serum 
Fw Forward 
GAPDH Glyceraldehyde 3-phospate dehydrogenase 
GFP Green Fluorescent Protein 
Gln (Q) Glutamine 
Glu (E) Glutamic acid 
GST Glutathione S-transferase 
H Hours 
HA Hemagglutinin 
H2O Water 
HBSS Hank’s Balanced Salt Solution 
HEK Human Embryonic Kidney 
HEPES 4-(2-hydroxyethyl)-piperazineethanesulfonicacid   
HF Heart Failure 
HI-FBS Heat Inactivated Fetal Bovine Serum 
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His (H) Hystidine 
HRP Horse Radish Peroxidase 
ICa,L L-type Calcium Current 
IGF-1 Insulin growth factor-1  
IGF1R Insulin growth factor-1 receptor     
IR Insulin receptor 
IRS Insulin receptor substrates 
Kb Kilo base    
KDa Kilo Dalton  
KO Knock Out         
Leu (L) Leucine        
LiAc Lithium Acetate   
Lys (K) Lysine 
LTCC L-Type Calcium Channel 
Mg2+ Magnesium ion 
MgCl2 Magnesium Chloride 
MHC Myosin Heavy Chain 
Min Minutes 
mOsM Milli Osmolar 
mRNA Messenger RiboNucleid Acid 
Na+ Sodium ion 
NaF Sodium fluoride 
Na3VO4 Sodium orthovanadate 
NP-40 Nonidet P-40 
O.D. Optic density 
OptiMEM Opti Modified Eagle’s Medium 
  8 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
PI3K Phosphatidyl-inositol 3-kinase  
PIP Phosphatidylinositol (3,4,5)-trisphosphate 
PLN Phospholamban 
PTEN                                   Phosphatase and TENsin homolog deleted on 
chromosome 10 
PVDF Polyvinylidene Fluoride 
Rw  Reverse 
RT Room Temperature 
Sec Seconds 
SD medium synthetic dropout medium 
SDS Sodium Dodecyl Sulfhate 
SDS-PAGE Sodium Dodecyl Sulfhate-Poly Acrylamide Gel 
Electrophoresis 
Ser (S) Serine 
SH2 Src homology 2 domain 
SH3 Src homology 3 domain 
SR Sarcoplasmatic Reticulum 
Thr (T) Threonine 
TEA TetraEthylAmmonium 
Trp (W) Tryptophan 
VGCC Voltage Gated Calcium Channel 
YFP Yellow Fluorescent Protein 
Y2H Yeast Two-Hybrid 
WT Wild Type 
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SUMMARY 
 
The insulin IGF1/Akt signaling pathway has recently been shown to be critical for 
the regulation of heart function and physiology. Indeed, compelling evidence 
shows activation of this pathway as one of the most important determinants for 
the enhancement of cardiac function and physiological growth in athletes, whereas 
its impairment is considered critical for the development of heart failure (HF). In 
this doctoral thesis, our aim was to determine the functional role of known and 
novel key-factors of this pathway to study whether their modulation might be 
envisaged as therapeutic tool for curing pathological cardiac hypertrophy (CH) 
and HF. 
 
Physiological CH is an adaptive response of the heart to stimuli, such as 
developmental growth and training and differs markedly from pathological 
hypertrophy occurring in patients with HF. In this thesis, we demonstrated the 
involvement of Akt kinase in regulating heart inotropism by modulating L-Type 
Ca2+ Channel (LTCC) density and function. In a mouse model with inducible and 
cardiac specific deletion of PDK1, the upstream activator of Akt, we found that 
the protein stability of the LTCC pore subunit (Cav!1) can be modulated by the 
kinase. In particular, phosphorylation of the C-terminal coiled coil of the Cav#2 
chaperone subunit enhances LTCC protein stability by prevention of PEST-
mediated Cav!1 degradation. Subsequently, to determine whether the  modulation 
of this mechanism may be used for the treatment of HF, we studied the fine-
regulation of LTCC density and activity by investigating the functional role of 
Akt-phosphomimetics Cav!2 constructs. Three Akt-phosphomimetic sequences 
corresponding to the Cav#2 C-terminal coiled coil were identified and shown to 
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protect Cav!1 from protein degradation, through an increase in the number of 
functional LTCC. Moreover, to establish whether the Akt-dependent 
phosphorylation of CaV#2 might be a trigger for the recruitment of other protein 
interacting partners, yeast two-hybrid screenings of human and mouse heart 
cDNA expression libraries revealed a fold-back interaction of the Akt-
phosphorylated-Cav#2 tail with a region of the Cav#2 globular domain. Co-
immunoprecipitation experiments confirmed this interaction, while negative 
results were obtained when Cav#2-WT was used as bait. This provided the proof 
of concept for a mechanism of action that relies on Akt-dependent 
phosphorylation. Site-specific mutagenesis in the identified interacting domain 
confirmed this mechanism. All togheter, we found that the Akt-dependent 
protective effect on Cav!1 stability might relay on Cav#2 structural 
rearrangements, which follow the phosphorylated C-terminal coiled coil fold back 
on its globular domain. 
 
In conclusion, results from this doctoral thesis provide further insights into the 
role of the insulin IGF1/Akt signaling pathway and its role in the modulation of 
myocardial physiology and HF. These findings may lead to the development of 
new therapeutical tools that will be useful for the modulation of impaired cardiac 
contractility in HF. 
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AIMS 
 
Compensatory mechanism that lead to myocardial hypertrophy include 
alterations in the regulation of signal transduction pathways involved in the 
control of cell size, protein synthesis, Ca2+ handling and energy metabolism. The 
re-establishment of cardiac function in HF could be envisaged by finding a new 
equilibrium favoring physiological rather than pathological CH. This can be 
reached by acting on downstream targets modulated by Akt kinase, a main 
mediator of the insulin IGF1 pathway by positively affecting cardiac inotropism 
by directly modulating cardiomyocyte Ca2+ handling. 
Accordingly, the main aims of the present Ph.D. thesis were: 
- to gain insight into the mechanism of action by which Akt intervenes in the fine-  
  regulation of heart inotropism by regulating Ca2+ current (ICa,L) and Ca
2+    
  handling; 
- to further demonstrate the pivotal role of Akt in the modulation of heart     
  inotropism by unraveling the molecular mechanisms by which Akt regulates L-      
  Type Calcium Channels density; 
- to further study the Akt-dependent fine-tuning regulation of LTCC density by 
searching for Akt-phosphomimetics CaV#2 sequences, which may increase 
orreestablish correct cardiac inotropism in HF by increasing the number of 
functional LTCC; 
- to further unravel the mechanism by which Akt intervenes in the modulation of 
Cav!1 protein stability by identification and characterization of possible Akt-
dependent protein interacting partners involved in LTCC complex structural and 
functional modulation. 
 
  12 
1. INTRODUCTION  
 
1.1. Heart failure 
 
Heart failure (HF), with an estimated prevalence of 1-2% in the Western world 
and an annual incidence of 5-10 per 1000, is a syndrome resulting from impaired 
ability of the heart to pump sufficient blood to the body, and thus matching the 
oxygen needs of peripheral tissues. Importantly, in people older than 50 years, 
the prevalence of HF increases progressively with age, making HF the leading 
cause of hospitalization in the elderly [sandoval1]. Despite the fact that HF 
management has been improved over the last decades, HF still results with a poor 
quality of life and reduced longevity [2] with a prognosis that has been described 
as being more malignant than cancer [3]. In fact, survival after the onset of HF is 
grim, with a 5-year survival rate as low as 25% and sudden death in up to 50% of 
HF patients. 
 
HF may have several etiologies either primary, starting from the myocardial 
tissue, or secondary and may be present under different clinical setting. Among 
the causes that lead to HF are coronary artery disease, hypertension, 
cardiomyopathies, valvular diseases, congenital defects, infectious diseases, 
diabetes and cardiotoxic substances (such as alcohol). Though no single causative 
mechanism or sequence of events has been found for HF, this syndrome is in 
general preceded by an initial insult (e.g., cardiomyocyte loss, persistently 
increased workload) responsible for impairing ventricular function in some way 
(Figure 1).  
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Figure 1. Schematic of principal events of heart failure onset. The compensatory mechanism summoned into action are 
often responsible for a paradoxical spiraling deterioration in cardiac structure and function, culminating in heart failure 
(from [4]). 
 
As a result, several mechanism, initially compensatory, such as activation of the 
rennin-angiotensin-aldosterone system, of the sympathetic adrenergic nervous 
system and increase of cytokine production may take place. The consequential 
increase in circulating neurohormonal factors and stimulation of stretch receptors 
result in increased heart size (cardiomegaly) via the enlargement of individual 
cardiomyocytes (hypertrophy). As largely recognized, the establishment of this 
pathological cardiac hypertrophy (CH) plays an important role in the onset of 
many forms of HF [5].  
 
  14 
Physiological CH is defined by augmentation of ventricular mass as a result of 
increased cardiomyocyte size and is the adaptive response of the heart to 
enhanced hemodynamic loads due to physiological stimuli such as postnatal 
developmental growth, training and pregnancy. In these cases, hypertrophy is 
characterized by enhanced cardiac function, normal sarcomere organization and a 
normal pattern of cardiac gene expression [6] without interstitial fibrosis or 
increased cell death. Importantly, physical training protects against cardiovascular 
disease and the resultant CH is usually beneficial [7]. Indeed, exercise training in 
HF after myocardial infarction enhances cardiac performance and aerobic exercise 
capacity and reverses pathological hypertrophy and remodeling both in 
experimental models and in patients [8]. On the other hand, CH is also observed in 
patients with pathological conditions such as hypertension, myocardial infarction, 
and valvular heart diseases. This type of cardiac growth is called pathological 
hypertrophy and is frequently associated with contractile dysfunction, interstitial 
fibrosis and re-expression of fetal-type cardiac genes such as atrial natriuretic 
peptide and !-myosin heavy chain [9, 10]. Therefore, in the short term, the 
adaptive response of the heart to enhanced hemodynamic loads apparently 
restores cardiovascular function (i.e., hypertrophy is adaptive). However, in the 
long run, the sustained activation of compensatory mechanism can lead to 
secondary heart damage, evidenced by worsening left ventricle (LV) remodeling 
(i.e., deleterious alterations in ventricular mass, chamber size and shape) and the 
hypertrophy becomes maladaptive, i.e., incapable of sustaining the hemodynamic 
burden. Indeed, patients undergo a transition from asymptomatic to symptomatic 
HF [11]. Clinically, this maladaptive hypertrophy has become recognized as a 
harmful reaction when generated by pathological stresses and is considered a major 
predictor for progressive HF and an adverse prognosis [12]. In fact, inhibition of 
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the development of pathological hypertrophy has been shown to have beneficial 
effects in animal models of pressure overload and is the target of some current 
therapies. Actual treatment of HF is based on the fact that neuroendocrine 
activation is important in the progression of the syndrome. In fact, therapeutic 
strategies that stem from the neurohormonal model (i.e., ACE inhibitors and beta-
blockers) prevent disease progression and reduce LV remodeling. Drugs derived 
from cardiorenal and cardiocirculatory models (diuretic and inotropes/vasodilators, 
respectively) provide symptom relief, but are less effective in reducing LV mass 
and improving prognosis [13]. Great advances have been made in the last decades 
in cardiac pathophysiology, but despite the knock-on effect this has had on the 
clinical management of HF, the syndrome is still a major killer and heart 
transplantation remains the ultimate treatment. Thus, new approaches are needed 
alongside conventional therapies to completely arrest LV pathological remodeling 
and progression to HF. Undoubtedly, further unraveling of the molecular 
mechanism governing cell size, protein synthesis and cardiac inotropism during 
HF is needed. This understanding will provide important information for the 
design of new therapeutic approaches to conquer this condition outright in the 
future. In particular, novel therapeutic interventions could be directed to take 
advantage of beneficial mechanism inherent to physiological stress-based 
hypertrophy that is via enhancement of important aspects controlled by the 
insulin IGF1/Akt pathway.  
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1.2. The IGF1/PI3K/Akt pathway 
 
The insulin growth factor-1 (IGF1)/phosphatidyl-inositol 3-kinase (PI3K)/Akt 
pathway plays a crucial role in a broad range of biological processes involved in 
the modulation of local responses as well as processes implicated in cell 
proliferation, transcription, translation, apoptosis and growth. The insulin 
pathway is also a critical regulator of glucose metabolism, promoting its uptake in 
the heart, glycolysis and glycogen synthesis as well as inhibiting fatty acid 
utilization [14]. Its important role in the regulation of cardiac growth, calcium 
handling and contractile function has been demonstrated. Indeed, impairment of 
this signaling pathway is now considered an important determinant of HF [15].  
1.2.1. Mediators of the signal transduction pathway 
1.2.1.1. IGF1 
IGF1 is a polypeptide growth factor that is characterized by insulin like short-
term metabolic effects and growth factor-like long-term effects on both cell 
proliferation and differentiation. IGF1 is produced in numerous tissues and 
particularly by the liver in response to growth hormone stimulation. Interaction of 
IGF1 (or insulin) with its receptor (IGF1R) activates the receptor’s cytoplasmatic 
tyrosine kinase activity, which in turn triggers phosphorylation of insulin receptor 
specific substrates (IRS). Phosphorylated IRSs then interact with cytoplasmic 
proteins containing src homology 2 (SH2) domains, such as PI3K. Within the 
target cells, activated PI3K then transduces the functional effects of IGF1, such as 
enhanced glucose transport, enhanced cardiomyocyte contractility and the 
inhibition of programmed cell death (apoptosis) [16]. 
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IGF1 is an important factor in the regulation of postnatal growth and 
development. In fact, knock out (KO) models of IGF1 or its receptor shows 
reduced body growth [14]. Both IGF1R and insulin receptor (IR) are present in 
the adult heart and have been shown to be essential for myocardial performance 
through the action of PI3K/Akt pathway [17]. In athletes, increased cardiac IGF1 
production is associated with physiological cardiac hypertrophy [18] and in 
transgenic (TG) mice with cardiac overexpression of IGF1R, physiological cardiac 
hypertrophy developed with increased myofiber size and enhanced contractile 
function [19, 20]. Cardiac-specific IR KO mice showed a decrease in heart size 
and impaired contractile function [21]. Intriguingly, when challenged by 
pathological hypertrophic stimuli, heart size was increased to a similar extent in 
both IR KO and wild type (WT) mice, even though IR KO heart size at baseline is 
smaller when compared to WT [22]. Thus, while the insulin/IGF1 pathway is 
involved in physiological hypertrophic growth, it does not appear to be necessary 
for pathological hypertrophy development. Indeed, cardiac-specific IGF1 
overexpression resulted in less cardiomyocyte death and fibrosis with chronic 
coronary artery narrowing [23] as well as reduced injury in an ex vivo model of 
ischemia/reperfusion [24]. However, although the short-term administration of 
IGF1 in animal studies has been reported to be beneficial by improving cardiac 
contractility and counteracting apoptosis, conflicting results has been shown from 
clinical trials in which IGF1 was administered chronically [25-27]. 
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1.2.1.2. Phosphoinositide 3-kinase (PI3K)  
PI3K is a member of the lipid kinase family involved in the phosphorylation of 
membrane phosphoinositides (PIP) [28]. The PI3K family comprises eight 
members divided into three classes according to their sequence homology and 
substrate preference (Table 1). 
 
 
 
Table 1. The PI3K family members (from [29] ). 
 
Class Ia  enzymes (p110!, p110# and p110") associate with a p85 regulatory 
subunit to form a heterodimeric complex. There are 8 isoforms of p85 encoded by 
three genes, each containing two SH2 domains that interact with 
phosphotyrosines on activated tyrosine kinase receptors (RTKs, e.g. growth 
factor receptors), antigen receptors and cytokine receptors.  
Class Ib enzymes are made up of only the p110$ catalytic and the p101 
regulatory subunit, which is activated by G-protein coupled receptors (GPCRs).  
Class II comprises three members (PI3KC2!, # and $) characterized by a 
carboxyl-terminal phospholipid-binding domain. While no regulatory subunit has 
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been identified, class II enzyme are predominantly membrane bound and activated 
by membrane receptors including RTKs, GPCRs, chemokines, and integrins.  
Class III kinase (VPS34p) is responsible for producing the majority of the cellular 
PtdIns-3-P and is involved in protein trafficking through the lysosome.  
 
Physiological hypertrophy involves activation of the PI3K (p110!) pathway, 
stimulated by RTKs, whereas pathological hypertrophy utilizes the GPCR-
induced PI3K (p110$) pathway [20]. Overexpression of a constitutively active 
(ca) PI3K (p110!) mutant resulted in cardiac hypertrophy in vivo to a similar 
extent to that seen in IGF1R TG mice [30]. In contrast, the physiological cardiac 
hypertrophy obtained by physically exercising mice, as well as in mice 
overexpressing IGF1R, was completely abolished by co-expression of a dominant 
negative (dn) PI3K (p110!) mutant [20]. 
 
PTEN (Phosphatase and TENsin homologue deleted on chromosome 10) 
antagonizes the activity of PI3K by catalizing conversion of active inositol lipids 
into inactive ones. In PTEN KO mice, increased PI3K (p110!) and PI3K (p110$) 
activity occurred in combination with increased cardiomyocyte size, while cardiac 
function was depressed [31]. 
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1.2.1.3. Akt 
Akt (also known as protein kinase B, PKB) is at the crossroad of the 
IGF1/PI3K/Akt physiological hypertrophy pathway and belongs to the family of 
the serine-threonine protein kinase. There are three closely related enzymatic 
isoforms Akt1 (PKB!), Akt2 (PKB#) and Akt3 (PKB$) (Figure 2), that play an 
important role in the regulation of cardiac growth, differentiation, survival, 
angiogenesis and contractile function, regulating a range of downstream targets [31, 
32]. 
 
 
 
Figure 2. Akt structure domains: an N-terminal pleckstrin homology (PH) domain, a central catalytic domain and a C-
terminal regulatory region with the two phosphorylation sites pT308 and pS473. (From [33] ) 
 
While Akt1 and Akt2 isoforms are widely expressed, Akt3 tissue distribution is 
primarily expressed in brain and testis [34]. The three Akt proteins (henceforth 
referred to as Akt) contain an N-terminal pleckstrin homology (PH) domain, a 
central catalytic domain and a C-terminal regulatory region (Figure 2). They are 
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similar both in structure and size and are thought to be activated by a common 
mechanism [35] . 
Akt is activated by IGF1 and insulin through PI3K. The resultant phosphorylated 
PIP products bind to the pleckstrin (PH) domain of Akt and induce its 
translocation from the cytosol to the plasma membrane where Akt becomes 
accessible for phosphorylation at Thr308 by phosphoinositide-dependent kinase-
1 (PDK1), which results in its activation [32] (Figure 3). 
 
 Figure 3. Schematic diagram of the upstream molecules involved in the activation of Akt and the major signaling 
pathways involved in protein synthesis  (From  [16]). 
 
Akt can also be phosphorylated at another regulatory phosphorylation site 
(Ser473) from the rapamycin-insensitive complex of the mammalian target of 
rapamycin (mTORC2)-comprised of  mTOR, rictor and G-beta-L/mMTST8 [36]. 
Akt is activated in response to physical exercise [20] and in caPI3K TG mice, but 
is repressed in dnPI3K TG mice [30]. Once fully activated, Akt migrates 
throughout the cell to several subcellular organelles and subdomains and 
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phosphorylates specific effector targets (Figure 3). Akt is eventually deactivated 
by dephosphorylation at T308 and S473 by protein phosphatase 2A (PPA2) and 
leucine-rich repeat protein phosphatase (PHLPP), respectively [37, 38]. 
 
1.2.1.3.1. Mouse models for studying the role of Akt  
 
Several cardiac-specific mouse models have been used for studying the 
physiological role of Akt and its upstream molecules in vivo. Most models include 
cardiac hypertrophy and maintenance or improvement of cardiac function. In fact, 
the Akt E40K mutant, which overexpresses a constitutively active form of Akt, 
induces a physiological type of hypertrophy together with an improvement in 
cardiac function [15]. The activated T308D/S473D mutant, which mimics the 
activated phosphorylation status, is also associated with heart enlargement due to 
an increase in myocyte size [39]. On the other hand, overexpression of 
myristilated Akt, that permanently confines Akt to the plasmamembrane in 
proximity to its activator PDK1, was found to be detrimental for cardiac function 
[40].  
 
Akt activation is increased 1.5-to 2-fold under physiological conditions in 
response to exercise training [20] and 6-fold in IGF1 TG mice [24]. It has been 
shown that short-term Akt activation or “physiological” activated Akt induces 
physiological hypertrophy, whereas prolonged Akt activation results in 
pathological hypertrophy with a drastic increase in heart size [40, 41]. These 
observation support the notion that the activation of the IGF1/Akt pathway may 
sustain either physiological or pathological hypertrophy, depending on the extent 
  23 
and timing of stimulation. 
In KO mouse model studies, deletion of a single or a combination of the various 
Akt isoforms resulted in a number of different phenotypes. Global Akt1 KO mice 
had a reduction in growth [42], while Akt2 KO resulted in insulin resistance and a 
mild growth delay [43]. On the other hand, Akt3 KO did not result in any growth 
problems but rather in a reduction in the size of brain cells [44]. 
1.2.1.3.2. Effects of Akt on Ca2+ -handling and contractility 
It has been reported that increased inotropism and calcium transient are typical 
features of isolated cardiomyocytes from exercised mice [45], HF patients 
subjected to acute IGF1 administration [46] and mice in which the 
IGF1/PI3K/Akt pathway has been activated [14]. As discussed in more detail in 
the paragraph 1.3. (Cardiac excitation-contraction coupling), contractility in 
cardiomyocytes is determined by the entrance of Ca2+ through the L-type Ca2+ 
channel (LTCC) and release of Ca2+ from the sarcoplasmatic reticulum (SR) 
through the ryanondine receptor (RyR). Relaxation  is mediated by Ca2+ reuptake 
into the SR through the SR Ca2+ ATPase pump (SERCA2A). As shown in Figure 
4, Akt seems to be involved in this process by the fine-tuning modulation of Ca2+ 
-handling. 
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Figure 4. Schematic diagram of some different signaling events involved in physiological and pathological hypertrophy. 
The PI3Ka dependent pathway is responsible for transcription of genes and increasing calcium-handling in the 
development of physiological hypertrophy triggered by IGF1. Activation of PI3Kg, through GPCR, is antagonistic and 
triggers various mitogen-activated protein kinase (MAPKs) pathways, which results in protein synthesis of fetal genes and 
differential activation of Akt. Moreover, it can be responsible for decreasing contractility through the inhibition cAMP 
production. Gas: G-alpha s proteins, Gai: G-alpha i proteins, Gbg: G-beta/gamma protein. From [16]. 
 
Overexpression of an active form of Akt1 results in improved cardiac inotropism 
both in vivo [15] and in vitro [47], augmenting Ca2+ current (ICa,L). Similar results 
were recently obtained in a mouse model with cardiac specific Akt1 nuclear-
overexpression [48] and in mice deficient for PTEN, an antagonizer of PI3K 
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activity [49]. In addition, activation or inhibition of Akt in cardiomyocytes as well 
as in neuronal cells has been shown to increase[32] {Viard, 2004 #1151;Blair, 
1999 #676;Catalucci, 2006 #28;Sun, 2006 #61} or reduce {Viard, 2004 
#1151;Blair, 1999 #676;Catalucci, 2006 #28;Sun, 2006 #61} ICa,L, respectively, 
suggesting a pivotal role of Akt in regulating LTCC function (Figure 5). 
 
 
 
Figure 5.  Diagram illustrating that the pathway IGF1/PI3K/Akt is involved in the modulation of the LTCC (from [50] ). 
 
1.3. Cardiac excitation-contraction coupling 
 
The ubiquitous second messenger Ca2+ is  essential in cardiac electrical activity 
and is the direct activator of the myofilaments, which cause contraction. Myocyte 
mishandling of Ca2+ is a central cause of both contractile dysfunction and 
arrhythmias in pathophysiological conditions. In healthy cardiomyocytes, 
electrical excitation starting during the upstroke of action potential leads to 
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cytosolic Ca2+ influx through opening of the LTCC [51, 52]. This triggers the 
calcium-induced calcium release (CICR) of intracellular Ca2+ from the SR through 
activation of the ryanodine receptor (RyR), eventually leading to cardiomyocyte 
contraction. The combination of Ca2+ influx and release raises the free intracellular 
Ca2+ concentration ([Ca2+ ]i), allowing Ca
2+ to bind to the myofilament protein 
troponin C, which then switches on the contractile machinery. For relaxation to 
occur, [Ca2+ ]i must decline, allowing Ca
2+ to dissociate from troponine. This 
requires Ca2+ transport out of the cytosol by different pathways involving, 
sarcolemmal Na+/ Ca2+ exchange (NCX), sarcolemmal SR Ca2+ -ATPase 
(SERCA2) or mithocondrial Ca2+ uniport [53](Figure 6). 
Figure 6. Ca
2+
 transport in ventricular myocytes and the time course of an action potential, Ca
2+
 transient and 
contraction (from [53] ). 
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1.4. Voltage-gated dependent Ca2+ channels 
 
LTCC belongs to the family of Voltage-gated dependent Ca2+ channels (VGCCs), 
that are activated in response to membrane depolarization and are essential in 
cytoplasmic Ca2+ signaling  processes in a variety of cells. VGCCs regulate a 
number of cellular processes including muscle contraction, secretion, 
neurotransmitter, gene regulation and neuronal migration. Two classes of VGCCs 
have been described and summarized in Table 2.   
 
 
Table 2. Ca2+channel types based on their electrophysiological and pharmacological properties. HVA is High-voltage 
activated and LVA Low-voltage activated, respectively (from  [54] ). 
 
The first class includes High Voltage Activated (HVA) channels, which are 
activated by strong depolarization. These are further classified according to their 
electrophysiological properties (activation threshold, conductance, time and 
voltage dependence of inactivation, selectivity to divalent cations, channel gating, 
open-and close-time duration) into the P/Q, N, R, and L-type [55, 56].  
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The second class of channels is Low-Voltage Activated (LVA) and consists of 
only T-type Ca2+ channels that open at low membrane potentials and inactivate 
very rapidly.  
 
1.4.1. Cardiac L-Type Calcium Channels structure 
 
L-type Ca2+ channels (“L”ong lasting) (LTCC) are often called dihydropyridine 
receptors (DHPR), because they are sensitive to various 1,4-dihydropyridines, 
some of them with either blocking (nifedipine, nicardipine) or increasing (Bay 
K8644) Ca2+ current regulatory effect. LTCC are distributed in various tissues 
such as skeletal muscle, heart, brain, neurons, endocrine [55]. 
Cardiac LTCC are composed of four polypeptide subunits comprising the Cav!1, 
Cav!2/", Cav# and form hetero-tetrameric complex with molecular mass of about 
400 kDa, which is considered the functional minimum core for Ca2+ channel 
assembly. In brain and skeletal muscle, Ca2+ channels have the fifth subunit 
(Cav$), but it’s not expressed in the heart [56-58]. The hydrophobic Cav!1 
polypeptide is entrenched in cell membrane, while Cav# subunit locates in 
cytoplasm. The Cav" subunit is anchored to cell membrane and has a single 
transmembrane segment with a short intracellular part and a long glycosylated 
extracellular part, while the Cav!2 peptide is extracellular subunit of the Ca
2+ 
channel. The Cav!2 and Cav" subunits of the LTCC are tightly bound together 
through a disulfide bridge. The accessory subunits (Cav#, Cav!2/") are tightly, but 
not covalently bound to the Cav!1 subunit and modulate the biophysical 
properties and trafficking of the Cav!1 subunit to the membrane (Figure 7).  
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Figure 7. Structural organization of the LTCCs. A) A Cav channel subunit assembly in the plasma membrane. Pore-
forming subunits Cav"1 complex with auxiliary subunits Cav!, Cav# and Cav"2/$ to form functional Cav channels in the 
plasma membrane (from [59]. B) The predicted membrane organization of the core subunits, their interactions, the 
structural domains of the auxiliary subunits presented here are described in detail in the text. (from [58] ) 
 
  30 
1.4.1.1. Cav"1 subunits 
 
The Cav!1 subunit (170–240 kDa) consists of four homologous motifs (I–IV), 
each composed of six membrane-spanning !-helices (S1-S6) linked by variable 
cytoplasmic loops (linkers) and a membrane-associated pore loop (P-loop) 
between the S5 and S6 segments (Figure 7B). This four homologous repeat 
structure endows the Cav!1 subunit with a Ca
2+ -conducting pore (ion-selective 
pore) controlled by voltage sensors and gating machinery (activation and 
inactivation gates). The S5 and S6 segments along with the P-loops form the pore 
lining of Cav channels [60-62]. There are four glutamic acid (EEEE) residues 
situated in the four P-loops, that are responsible for selective filtration of Ca2+ and 
form a Ca2+ selectivity filter [63]. 10 Cav!1 subunit genes have been identified and 
separated into 4 classes (Figure 8): Cav1.1 (!1S), 1.2 (!1C), 1.3 (!1D), and 1.4 
(!1F). Only the Cav!1C (dihydropyridine-sensitive [DHP-sensitive]) subunit is 
expressed in high levels in cardiac muscle. In brain, Cav2.1 (!1A), 2.2 (!1B), and 
2.3 (!1E) form P/Q-, N- and possibly R-type channels, respectively. These are 
primarily responsible for initiation of synaptic transmission at fast synapses in 
the nervous system.  
 
   
Figure 8. Predicted topology and nomenclature of Cav! channel subunits (from  [59]). 
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Cav3.1 (!1G), 3.2 (!1H), and 3.3 (!1I) form T-type channels that are localized into 
the brain, kidney, and heart and were originally called Low-Voltage–Activated 
channels. Unlike L-type channels, they are relatively insensitive to DHPs. Cav3 
channels conduct T-type Ca2+ currents, which are important in a wide variety of 
physiological functions, including neuronal firing, hormone secretion, smooth 
muscle contraction, cell proliferation and myoblast fusion. In the heart, T-type 
channels are abundant in sinoatrial pacemaker cells and Purkinje fibers of many 
species and are important for maintenance of pacemaker activity by setting the 
frequency of action potential (AP) firing [58]. 
 
Different KO mice lacking Cav1.2 or Cav1.3 were generated to study the 
pathophysiological roles of LTCC in vivo. As showed in Figure 9, some of the 
LTCC roles as mediators of signaling between cell membrane and intracellular 
processes like blood pressure regulation, smooth muscle contractility, insulin 
secretion, cardiac development has been elucidated. In particular, conditional 
Cav1.2 ko mice show several cardiovascular and visceral phenotypes, while 
Cav1.3 null mice are viable but completely deaf and with sinoatrial node 
dysfunction, such as arrythmia and bradicardia [64]. 
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Figure 9. Distribution and function of LTCC subtypes Cav1.2 and 1.3 revealed by transgenic mouse models. (from  [64]). 
 
1.4.1.2. Accessory subunits 
 
1.4.1.2.1. Cav"2/$ subunits 
 
Four genetically distinct Cav!2/" subunits (Cav!2/"1, 2, 3, 4) have been described, 
each one of these is differentially expressed in various tissues, including skeletal 
muscle, heart and brain [65-67]. 
The Cav!2" subunits are closely associated with the Cav!1 subunit by surface 
interaction and are intracellularly linked through a disulfide bridge to a small 
protein, the Cav" subunit (Figure 7). The Cav!2 subunit is entirely extracellular, 
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while the Cav" subunit has a single transmembrane region with a very short 
intracellular part. The Cav!2 and Cav" subunits are encoded by the same gene, 
which is separated by proteolytic cleavage [65]. In heterologous expression 
systems, coexpression of the Cav!2/" subunit affects Cav!1 function by increasing 
channel density, charge movement, and maximal binding capacity (Bmax) of drug 
binding (e.g., the DHP isradipine) with smaller effects on dissociation constant 
(KD) and variable minor effects on channel kinetics [68, 69]. The Cav!2/" subunit 
allows an enhancement in the membrane trafficking of the Cav!1, associated with 
an increase in the number of ligand binding sites. In addition, coexpression of the 
Cav!2/" subunit causes an increase in current amplitude, faster activation and 
inactivation kinetics [70]. 
 
1.4.1.2.2. Cav! subunit  
1.4.1.2.2.1. Cav! subunit structure 
 
Four distinct genes encode the Cav# subunit isoforms (Cav#1–#4) and numerous 
splice variants for each gene are known [71](Table 3). 
Table 3. The Ca2+ channel ! subunits-classification and tissue distribution (from [54]). 
 
Cav#1–#4 (54 kD) is the only subunit of the channel that is entirely cytosolic and 
has a common structure consisting of five different domains, with the two central 
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domains sharing significant homology amongst the Cav# subunits [72] (Figure 7-
10B). The amino and carboxy termini are relatively less well conserved. Cav# 
subunits associate with the Cav!1 subunit predominantly through a highly affinity 
interaction that is mediated by the Alpha interaction domain (AID) in the Cav!1 
subunit [73] and a corresponding Beta interaction domain (BID) in the Cav# 
subunit [74] (Figure 7B-10A). 
 
 
 
Figure 10. A) Predicted topology and nomenclature of the Cav! channel accessory subunits (from  [59]). B) Structure of a 
complex between the Cav! subunit and the AID of the Cav"1. AID complex is shown as a ribbon representative, Cav! 
consists of an SH3 domain (blue) and a guanylate kinase (GK) domain (red). Two long helices ("1 and "2; grey) are 
appended onto the SH3 domains of Cav! subunits. The AID (yellow) binds into its pocket on the opposite side of the GK 
domain from the SH3. The central variable region would fall in the gap that is visible between "2 and !5 (from [75].  
 
Despite the ability of Cav# subunits to form heterogeneous complexes, it is clear 
that each type of channel has a predominant Cav# subunit associated with it. 
Cav#4 is the predominant subunit associated with the P/Q-type channels, the N-
type channels predominantly contain Cav#3, whereas L-type channels contain 
Cav#2.  
In the heart, Cav#2 is encoded by Cacnb2 gene  and evaluation of the 3D structure 
showed that is structured in a globular portion (aa 1-460) and in a coiled coil 
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region (aa 461-655, in blue), which contains the predicted Akt consensus site 
(RPDRS) (Figure 11) [75, 76].  
The amino acidic sequence of 655 aa is: 
 
 
 
Figure 11. Cacnb2 amino acidic sequence (655 aa). The globular portion is not highlighted (1-460 aa), the BID sequence 
(212-252 aa) is highlighted in grey, the coiled-coil region is highlighted in light blue (461-655), the Akt consensus site is in 
yellow (500-504). 
 
1.4.1.2.2. The roles of the Cav! auxiliary subunits  
 
The Cav! subunits have marked effect on LTCC channel expression and 
modulation of the pore-forming Cav!1 subunit. It has been shown that 
overexpression of the Cav#s subunit increased the density of endogenous calcium 
currents, indicating an increase in the functional expression of Cav!1 subunits [77, 
78]. The Cav# subunits aid in the trafficking of Cav!1 to the plasma membrane, 
partly by its ability to mask an endoplasmic reticulum retention signal in the 
Cav!1 subunit [79]. In addition to its role in membrane trafficking, the Cav# 
subunits modulate a host of biophysical properties of the channel with 
characteristics to the Cav!1-# combination. The Cav# subunits can accomplish 
these dual functions independently, as illustrated by their ability to modulate the 
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biophysical properties of channels in the presence of a mutation in the AID 
region, which disrupts its ability to enhance membrane trafficking of Cav!1 [80]. It 
has been suggested that this is due to the ability of some Cav# subunits to 
associate with other intracellular loops of the channel through weaker interactions. 
This supports a model in which the conserved high-affinity binding of the Cav# 
subunit to the AID anchors it to the Cav!1 subunit and facilitates low-affinity 
interactions of other Cav# subunit domains/regions with different parts of the 
Cav!1 subunit, which in turn are responsible for the modulation of gating [81].  
All four Cav# subunit isoforms hyperpolarize the voltage-dependent activation of 
all HVA. In contrast, steady-state inactivation properties reveal differences, both 
with regard to different Cav!1 and different Cav# subunits. In general, the Cav#1,3,4 
subunits expressed with Cav!1 result in hyperpolarization of voltage-dependent 
inactivation, so that channels inactivate at more negative potentials and speed up 
the inactivation kinetics. On the other hand, partly due to palmitoylation of two 
cysteines in its N-terminus, the rat and human Cav#2a subunit depolarizes the 
voltage dependance inactivation, making the channels inactivate at more positive 
potentials, and dramatically slowing down the kinetics of inactivation [82]. 
Regulation of calcium channel activity also occurs through modification of the 
Cav# subunits. Cav#2a is a substrate for protein kinase A (PKA) and 
phosphorylation of Cav#2a is important for the ability of PKA to stimulate the 
currents generated by the Cav!1 2.1 channels in mammalian expression systems 
and in cardiac myocytes [83]. The Cav# subunit also plays a role in the 
modulation of the Cav!1 2.2 channels through the mitogen-activated protein kinase 
(MAPK) pathway [84]. It is clear that the functional effects of the Cav# subunits, 
and hence the calcium channels, can be modulated in response to a variety of 
cellular stimuli. Stimulus induced modification of the auxiliary subunits may 
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provide an additional level of modulation of intracellular communication mediated 
by the LTCC. 
 
1.4.1.2.3. Role of accessory subunits in disease 
 
Mutations or deletions of Cav# subunit result in a discernible phenotype and a 
loss of normal function in mouse models. KO mouse model of the Cav#1 isoform 
resulted in a lethal phenotype with reduced skeletal muscle mass and structural 
abnormalities. On the other hand, heterozygotes mice were asymptomatic, 
indicating that residual amount of Cav#1 subunit, is sufficient for normal 
physiological activity [85].  
Deletion of Cav#2 gene gave rise to an embryonic lethal phenotype, presumably 
because of cardiac defects, thus underlining the essential role of Cav#2 in cardiac 
contraction. In contrast, KO of the Cav#3 isoform appear to be normal in 
appearance with no obvious phenotype in the heart, lung, kidney, spleen, 
pancreas, liver, ovary or testis, indicating that other Cav# subunits are able to 
substitute for its function [86]. As described in Table 4,  deletions or mutations of 
the auxiliary subunits in many mouse models result in a phenotype with a loss of 
normal functions and severe physiological consequences, further emphasizing their 
role in maintaing normal neuronal and muscular function. 
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Table 4.  Spontaneous mutations and targeted deletions of the auxiliary subunits in mice (from  [87]). 
 
1.5. Regulation of intracellular Ca2+: cardiac dysfunction 
 
The importance and ubiquity of Ca2+ as an intracellular signaling molecule suggests 
that altered channel function could give rise to widespread cellular and organ 
defects. Indeed, a variety of cardiovascular diseases, including atrial fibrillation, 
heart failure, ischemic heart disease, Timothy syndrome, and diabetic 
cardiomyopathy have been related to alterations in the density or function of the 
LTCC [58, 88-90]. However, the molecular basis for dysregulation of LTCC 
function and the possible involvement of Akt in ICa,L regulation remains 
unresolved.  
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1.5.1. LTCC in Heart Failure, Diabetic Cardiomyopathy and Atrial Fibrillation 
 
It is evident that EC coupling in the heart depends on the function of the LTCC, 
but the consequence of increased/decreased Ca2+ channel density in hypertrophy 
and cardiac failure remains speculative. Most investigators report no change in the 
LTCC or downregulation in end-stage HF, but there is an agreement that alteration 
of intracellular Ca2+ handling in the myocardium is relevant to both human and 
animal models of heart disease [91]. A significant increase in the number of Cav!1 
subunits was found in hypertrophied hearts compared to normal hearts [92].  
Impaired Ca2+-induced Ca2+ release in obesity-linked type 2 diabetes underlies 
depressed cardiac function, showing that the contractile dysfunction linked with 
the cardiomyopathy can be explained by disturbed Ca2+ cycling, reduced Ca2+ 
influx via LTCC, lowered Ca2+ reuptake and increased Ca2+ efflux [88]. During the 
early phase of electrical remodeling in a rabbit model of rapid atrial pacing, a 
reduction in Cav#2 subunit expression paralleled a reduction in IcaL prior to 
changes in the Cav!1c subunit mRNA levels. These data supports the evidence 
that reduced expression of Cav# subunits is responsible for the reduction of 
functional LTCCs [93].  Moreover, mutations of the G406R as well as G402S in 
the Cav!1c subunit were found in patients identified with Timothy Syndrome, a 
disease characterized by syncope and sudden death from cardiac arrythmias [94]. 
Based on these evidences, it appears clear that LTCCs play a key role in HF, 
Diabetic CardioMyopathy (DCM), Atrial Fibrillation (AF) and Timothy 
Syndrome. 
 
 
 
  40 
1.5.2. L-type Calcium Channel abundance and function 
 
Cardiac LTCCs are the main entrance for Ca2+ influx into cardiac cell and 
determine the activity of the whole heart. Therefore, changes in channel expression 
and regulation may alter the heart activity and badly influence functions of whole 
body. Despite some reports where LTCC density were shown increased in 
hypertrophied and failing hearts, many researchers demonstrated that HF is 
associated with reduction or no change of LTCC density and IcaL.  
In failing heart not only cardiac remodeling happens, but also alteration of several 
regulatory systems. In ischemic and failing heart, the sympathetic system is 
activated and the level of catecholamines is raised. Consequently, the #-adrenergic 
receptors (#-AR) are activated and the LTCC stimulation occurs through cAMP. 
In patients with HF, this pronounced activation of the sympathetic system is 
inversely correlated with survival. Indeed, the level of cardiac #-ARs in failing 
heart is reduced and the #-AR-Gs coupling of remaining receptors is altered. #-AR 
blockade is a widely used treatment in HF, when cardiac activity is regulated by 
cAMP-dependent cascade suppression [89]. 
Alterations in the peak of IcaL have been documented in hypertrophic states 
induced in various animal models [95]. To a large degree, the development of 
severe hypertrophy and CHF in animal models is associated with abnormalities in 
LTCC abundance and/or function. However, abnormalities in LTCC function are 
not consistently manifest in milder forms of cardiac pathologies. Alterations in 
LTCC function with end-stage human CHF remain equivocal. With mild/moderate 
(compensated) hypertrophy, basal ICa,L may be unchanged, or even increased, 
from control values. Nevertheless, a reduction in the #-AR mediated augmentation 
of ICa,L is an early event in the transition from hypertrophy to CHF. With the 
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development of severe hypertrophy and/or CHF, basal ICa,L is, in general, reduced 
from the control values. One possible explanation for these findings is that 
abnormalities in the #-AR signal transduction pathway occur early in the 
transition from hypertrophy to failure. Specifically, the number of #-ARs may be 
reduced and may be associated with a reduced capacity for cAMP production. In 
addition, the phosphorylation capacity of the LTCCs can be reduced with the 
progression of this disease process. The reduction of ICa,L with severe 
hypertrophy and/or failure may be associated with a reduction in the abundance of 
LTCCs (Figure 12 from [89]). 
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Figure 12. Schematic representation of changes in LTCC abundance and function during the progression of a cardiac 
pathologic process. Changes in basal LTCC abundance and function with the progression of the disease process are shown 
on the left and changes in !-AR mediated augmentation of LTCC function are shown on the right ( from [89]). 
 
While the development of cardiac hypertrophy and CHF have been associated 
with abnormalities in specific components of the #-AR transduction pathway and 
may lead to diminished #-adrenergic-mediated augmentation of the L-type Ca2+ 
current, inherent defects in the phosphorylation potential of the LTCC 
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themselves cannot be ruled out. Specifically, a differential expression of the LTCC 
subunit isoforms with the development of cardiac hypertrophy and/or failure may 
lead to altered subunit isoform assembly of the LTCC [89]. 
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2. METHODS 
 
2.1. Generation of Genetically Modified Mice.  
 
Cardiac-specific PDK1 inducible (MerCreMer-!-MHC PDK1) knockout mice 
(kindly given by Dr.Dario Alessi) were generated by breeding PDK1floxed/floxed 
transgenic mice where exon 3 and 4 of the pdk1 gene were flanked by loxP excision 
sequences [96], with mice expressing the cardiac-specific MerCreMer-!-MHC 
promoter-driven Cre recombinase gene (kindly given by Dr.Jeffrey D.Molkentin) 
[97]. The resulting background strain of the MerCreMer mice was C57BL/6-
SV129 and was unchanged throughout all experiments. Control animals used in 
this study were PDK1floxed/floxed littermates not expressing the cre recombinase 
gene and were treated with the same tamoxifen regiment. Tamoxifen dissolved in 
corn oil was injected intraperitoneally once a day for 6 days at a dose of 75 %g/g 
body weight. Male animals 7-8 weeks old were used.  
All animal procedures were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals and approved by the Institutional Animal Care 
and Use Committee. 
 
2.2. Cell culture, transfection  and treatment of cells 
 
2.2.1. Isolation of adult ventricular myocyte  
 
Cardiomyocytes were dissociated from the ventricles of 4 month-old-mice, by 
methods previously described [98]. Briefly, the heart was rapidly excised and 
placed in Tyrode solution containing (in mM): 120 NaCl, 5.4 KCl, 1.2 NaH2PO4, 
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5.6 glucose, 20 NaHCO3, 1.6 MgCl2, 10 2,3-butanedione monoxime (BDM) and 
taurine 5 (buffer A). The heart was retrogradely perfused with buffer A for 4-5 
min, then with buffer A containing 1 mg/ml trypsin and 4 mg/ml liberase 4 
blendzyme (Roche) by the Langerdorff method at 37°C. After 2 min of enzyme 
perfusion, 50 %M Ca2+ was added to the enzyme solution. After !5 min of 
digestion that the heart became ”swollen and soft”, the enzyme was ricirculated 
and the heart was perfused for an additional 8-12 min or until flow rate surpassed 
pre-enzyme flow rate. Only Ca2+ tolerant cells with clear cross striations and 
without spontaneous contractions or significant granulation were selected for the 
experiments of Ca2+current measurement and fluorescent measurement of [Ca2+]i. 
Isolated cells were plated in dishes precoated with 20 %g/mL laminin 
(Collaborative Biomedical Products) in DMEM (Sigma) supplemented with 1 
mM CaCl2, 15 mM BDM, 25 mM HEPES and 100 U/ml penicillin and 0.1 mg/ml 
streptomycin (Euroclone). Cells were infected with an adenovector expressing 
either no transgene (mock), HA-E40K-Akt (AdAkt) or Akt-K179M (AdAktDN) 
at MOI 100 and harvested 48 h post infection. The viral vector was amplified and 
purified in 3% Sucrose/PBS by ViraQuest, Inc. 
 
2.2.2. Cell lines and transfection 
 
293T cells (Human Embryonic Kidney) were used for western blot analysis, 
calcium assay and electrophysiological experiments. This cell line was grown in 
DMEM (Sigma) with 10% HI-FBS (Invitrogen) and 100 U/ml penicillin and 0.1 
mg/ml streptomycin (Euroclone). Transfection of 293T cells was performed in 
serum-starved medium (Opti-MEM I reduced-serum medium, Invitrogen) by 
using LipoFectamine2000 (Invitrogen) according to the manufacture’s 
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instructions.  
293T cells were plated at 70% confluence in a 60 mm Petri dish in OptiMEM 
(Invitrogen) and co-transfected with a DNA mix containing 1 %g of a plasmid 
encoding GFP-Cav!1, 2 %g of a plasmid encoding Cav!2 subunit (either Cav!2-WT 
or Cav!2-SE), 2%g of a plasmid encoding Cav#2-XB, -XX, -Akt or Cav!2-SE-XB,-
XX, -Akt or 1 %g of a plasmid encoding GFP-Cav!1 together with 2 %g of a 
plasmid encoding Cav!2-K141Q, -K149Q, -K161Q, -K149-161Q or Cav!2-SE-
K141Q, -K149Q, -K161Q, -K149-161Q. After 48 h, cells maintained in serum-
free condition were used for western blot or calcium assay experiments. 
 
For electrophysiological recordings of recombinant Cav!1 currents, experiments 
were performed as followed: 293T cells were plated at 50-70% confluence in a 35 
mm Petri dish in OptiMEM (Invitrogen) and transfected with a DNA mix 
containing 1 %g of a plasmid encoding YFP-Cav!1, 2 %g of a plasmid encoding 
Cav!2 subunit (either Cav!2-WT or Cav!2-SE or Cav!2-SE-XB,-XX, -Akt), 0.5%g of 
a plasmid encoding Cav!2"1 subunit and 0.1 %g of a plasmid encoding CD8. After 
24 h, cells were plated at low density ~35x103 cells per 35 mm Petri dish in 
DMEM with or without 10% FBS for 36 h and electrophysiological recordings 
were performed on cells expressing both YFP-Cav!1 and CD8, which is identified 
using anti-CD8 coated beads (Dynabeads, Dynal).  
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2.3. Ca2+ analysis  
 
2.3.1. Ca2+ current measurement. 
 
Macroscopic ICa,L was recorded at room temperature (~22 °C) using the whole-cell 
patch clamp technique with an Axopatch 200B amplifier (Axon Instruments, CA, 
USA) as previously described in native cells {Maier, 2003 #1204;Aimond, 2005 
#1575}. External recording solution contained (in mM): 136 TEA-Cl, 2 CaCl2, 1.8 
MgCl2, 10 HEPES, 5 4-aminopyridine and 10 glucose (pH 7.4 with TEA-OH). 
Pipette solution contained (in mM): 125 CsCl, 20 TEA-Cl, 10 EGTA, 10 HEPES, 
5 phosphocreatine, 5 Mg2ATP, and 0.3 GTP (pH 7.2 with CsOH). Myocytes 
were held at -80 mV and 10 mV depolarizing steps from -50 mV to +50 mV for 
300 ms were applied. Analysis was performed using a microscope (Diaphot 200, 
Nikon) equipped with 10x NA 20 objective lenses (CFWN, Nikon) and 
pCLAMP9 (MDS Analytical Technologies) was used as acquisition software. 
Recording solutions allowed for the specific measurement of the Ca2+ current in 
the absence of contaminating Na, K, or Na-Ca2+ exchange currents.  
 
For electrophysiological recordings of recombinant Cav!1 currents in cotransfected 
cells, the extracellular solution contained (in mM): 135 NaCl, 20 TEACl, 5 CaCl2 , 
1 MgCl2 and 10 HEPES (pH adjusted to 7.4 with KOH, ~330 mOsM). 
Borosilicate glass pipettes have a typical resistance of 1.5-3 M& when filled with 
an internal solution containing (in mM): 140 CsCl, 10 EGTA, 10 HEPES, 3 Mg-
ATP, 0.6 GTP-Na and 2 CaCl2 (pH adjusted to 7.2 with KOH, ~315 mOsM). 
Analysis was performed using a microscope (x71, Olympus). Data acquisition 
was performed with pCLAMP9 software. 
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2.3.2. Fluorescent measurement of [Ca2+]i 
 
Isolated myocytes were loaded with 5 %M Fura-PE3 acetoxymethyl (AM) ester 
(TefLabs) which was dissolved in DMSO (Sigma) containing 0.02% pluronic acid 
for 30-35 min in buffer A (in mM: 120 NaCl, 5.4 KCl, 1.2 NaH2PO4, 5.6 glucose, 
20 NaHCO3, 1.6 MgCl2, 1 Ca 
2+ and 5 taurine) and analyzed as previously 
described {DeSantiago, 2002 #1201;Bassani, 1994 #1202}. The Fura-PE3 
fluorescence ratio was determined at RT using a Diaphot 2000 microscope, 
operating at an emission wavelength of 510 nm with excitation wavelength of 340 
and 380 nm. The stimulating frequency for Ca2+ transient measurements was 0.5 
Hz. Baseline amplitude (estimated by 340 nm/380 nm ratio) of the Ca2+ signal was 
acquired and data were analyzed using software from IonWizard (IonOptix).  
 
 
2.3.3. Calcium Assay  
 
2.3.3.1. Principle 
 
The  FLIPR Calcium 5 Assay kit (Molecular Devices) was used for this assay and 
it provides a reliable fluorescent-based assay for detecting changes in intracellular 
calcium. During incubation, the indicator passes through the cell membrane and 
esterases in the cytoplasm cleave the AM portion of the molecule. After 
incubation, the cells are ready to be assayed. The masking dye does not enter the 
cell, but significantly reduces background originating from residual extracellular 
fluorescence of calcium indicator, media and other components. Once the target is 
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activated, direct measurement of intracellular fluorescence change due to increased 
calcium concentration is enabled (Figure 13). 
 
 
 
 
 
 
 
 
 
 
Figure 13. The FLIPR Calcium Assay kit principle for detecting changes in the intracellular calcium. 
 
2.3.3.2. Procedure 
 
Transfected 293T cells were seeded overnight in a 96 well plate at density 
~50x103. Cells were incubated with 100 %l of Loading Buffer (Calcium 5 Assay 
Reagent Component A + 1X HBSS Buffer with 20 mM HEPES pH 7.4) for 1h at 
37°C, 5% CO2, without removing the supernatant. A final concentration of 1 %M 
Bay K8644 (Sigma Aldrich) as LTCC agonist was added per well with the 
dispenser during detection on the Synergy 2 with the following fluorescence 
parameters: 
- Excitation wavelength: 485/20 nm 
- Emission wavelength: 528/20 nm 
- Automatic emission cut-off: 510 nm 
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The calcium kinetic collecting data last 1,30 min per well and the acquisition time 
was every 5 seconds. Results are expressed as relative fluorescence units (RFU) 
and were analyzed using Prism Software (GraphPad Software). Each experiment 
(n=8) is representative of a total of four independent FLIPR experiments. 
 
2.4. Molecular cloning 
 
2.4.1. Preparation of plasmids  
 
Cacnb2 cDNA (complete coding sequence, cDNA clone MGC: 129335, IMAGE: 
40047531; ATCC #10959168) was cloned in pcDNA3 vector. Site-directed 
mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene). Cav!1 PEST deletion mutants and GFP fusion proteins were 
generated by PCR. YFP-Cav!1 expression plasmids were provided by N.Soldatov 
(National Institute on Aging, National Institutes of Health, Baltimore, MD, USA). 
A lentivirus vector was generated and used as an expression vector for siRNA-
mediated silencing of the akt gene (siAkt). The sequence used (5’-
tgcccttctacaaccaggatt-3’) was chosen in a conserved region between rat, mouse, 
human and has been validated for targeting Akt-1 and -2. All constructs were 
confirmed by DNA sequencing.  
 
2.4.2. DNA transformation (Heat Shock method) 
 
The ligated DNA (5 %l), pure plasmid DNA (100 ng) or mutagenesis PCR product 
(2 %l) was added to 50 %l of competent cells (DH5!, Invitrogen or XL10Gold, 
Stratagene), which were pre-thawed on ice. The mixture was incubated on ice for 
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30 min, heat-shocked for 2 min at 37°C water and immediately put back on ice for 
1 min. 250 %l pre-warmed LB was added to the mixture, followed by shaking at 
37°C for 1h. Everything was spread on LB agar plates containing the appropriate 
antibiotic. 
 
2.4.3. DNA ligation 
 
50 ng of vector DNA and 3-fold molar excess of insert was combined, followed by 
addition of T4 ligase (1U/%l) and 10X Ligation Buffer (New England Biolabs). The 
total volume was adjusted with H2O to 10 %l and the mixture was incubated ON 
at 16°C. 5 %l of the ligation producted was used for transformation. 
 
2.4.4. DNA preparation 
 
2.4.4.1. Small-scale preparation 
 
The Wizard Plus SV Minipreps DNA Purification System (Promega) provides a 
simple and reliable method for rapid isolation of small-scale plasmid DNA. 5 ml 
overnight bacteria culture was harvested by centrifugation for 5 min at 5000 x g 
and the supernatant was discarded. Pellet was completely resuspended in Cell 
Resuspension Solution [50 mM Tris-HCl (pH 7.5), 10 mM EDTA and 100 %g/ml 
RNase A] by vortexing, followed by the addition of Cell Lysis Solution (0.2 M 
NaOH and 1% SDS). After incubation of the mixture for 5 min at RT, Alkaline 
Protease Solution was added, followed by another 5 min incubation. The bacterial 
lysate was centrifuged at 14000 x g for 10 min, immediately after the addition of 
Neutralization Solution (4.09 M guanidine hydrochloride, 0.759 M potassium 
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acetate and 2.12 M glacial acetic acid, pH 4.2). The cleared lysate was transferred 
to the Spin column and centrifuged for 1 min at 14000 x g at RT. Column Wash 
Solution [162.8 mM potassium acetate, 22.6 mM Tris-HCl (pH 7.5) and 0.109 
mM EDTA (pH 8.0) previously diluted with 95% ethanol was added to the Spin 
Column, followed by another centrifugation. The wash procedure was repeated 
one more time eluting the DNA with Nuclease-Free Water or TE buffer [10 mM 
Tris-HCl (pH 7.5) and 1 mM EDTA]. 
 
2.4.4.2. Large-scale preparation 
 
Large-scale plasmid DNA isolation was carried out by using the Pure Yield 
Plasmid Maxiprep System (Promega), according to the manifacturer’s instruction. 
The 200 ml overnight bacteria culture was harvested by centrifugation for 10 min 
at 5000 x g and the supernatant was discarded. The pellet was completely 
resuspended in Cell Resuspension Solution by vortexing, followed by the addition 
of Cell Lysis Solution. The bacterial lysate was centrifuged at 14000 x g for 20 
min, immediately after the addition of Neutralization Solution. Then the 
supernatant was poured into PureYield Maxi Binding Column and it was applied 
maximum vacuum, followed by washing with Endotoxin Removal Wash 
(previously diluited with isopropanol) and Column Wash. The DNA was eluted 
in Nuclease-Free Water before centrifugation at 2000 x g for 5 min. 
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2.4.5. DNA purification 
 
The Wizard SV Gel and PCR Clean-Up System (Promega) is designed to extract 
and purify DNA fragments of 100bp to 10kb from standard agarose gel or to 
purify PCR products directly from a PCR amplification. 
The DNA was excided from the agarose gel with scalpel and weighted. Three 
volumes (100 mg !100 %l) of Membrane Binding Solution [4.5 M guanidine 
isothiacyanate, 0.5 M potassium acetate (pH 5)] were added to solubilize the gel 
slice completely by incubating at 55°C for 5 min. 
An equal volume of Membrane Binding Solution was added to PCR reactions. 
The dissolved gel mixture or prepared PCR product were transferred to SV Spin 
Column and, after an incubation of 1 min at RT, centrifugated at 16000 x g for 1 
min. The column was washed twice with Membrane Wash Solution [10 mM 
potassium acetate, 80% ethanol, 16.7 %M EDTA (pH 8)]. The DNA was eluted 
in Nuclease-Free Water before centrifugation at 14000 x g for 1 min. 
 
2.4.6. PCR (Polymerase chain reaction) 
 
PCR was performed by using the Platinum Pfx DNA Polymerase kit (Invitrogen) 
and the primers were synthetized by Primm, Milan (Italy). 
Three different nucleotide sequences encoding either the whole CaV!2 terminal 
coiled coil region or two shortest sequences encompassing the Akt consensus site 
(RXXRS/T) were cloned in pcDNA3 vector. Cacnb2 wt and Cacnb2-SE (Ser625 
of the Akt consensus site was replaced by Glutamate to mimic Akt 
phosphorylation, S625E) were used as template. 
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Three couples of oligonucleotide containing the XbaI (tctaga) and BamHI (ggatcc) 
restriction sites were designed for PCR amplification: 
1) #2 -XB, #2 -SE XB: 585 bp (1383-1965 nt Cacnb2 ) 
  Xba Fw : 5’gctctagaatgccaccctcccagcggtaacctcc 
  Bam Rw : 5’gggatcccgctggagccactctgttgagatggca 
2) #2 -XX, #2 -SE XX: 273 bp (1383-1656 nt Cacnb2) 
 Xba Fw: 5’gctctagaatgccaccctcccagcggtaacctcc 
 X 1 Rw: 5’cgggatcctcaagagtcaaacgtctcttgcctagagagg 
3) #2 -Akt, #2 -SE Akt, lenght insert: 108 bp (1458-1566 nt Cacnb2) 
 Akt Fw: 5’gctctagaatgcccaccctcgcctctaattcacagggttt 
           Akt Rw: 5’cgggatcctcatttgacgggttctaggcaaggttcttcttc 
 
The PCR reaction was performed by a DNA pre-denaturation for 5 min at 94°C 
and followed by 5 cycles of DNA denaturation at 94°C for 30 sec, primer 
annealing at 66°C for 30 sec and DNA extension at 72°C for 1 min and by 25 
cycles of DNA denaturation at 94°C for 30 sec and DNA extension at 72°C for 1 
min. The reaction was maintained at 4°C after a final step of DNA extension at 
72°C for 10 min. 
The following PCR conditions were used: 
                    
Mix Volume 
10X Pfx Amplification Buffer 5 %l 
10mM dNTP mixture 1.5 %l 
50mM MgSO4 1 %l 
primer mix (10 %M each) 1.5 %l 
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template DNA (100ng) x %l 
Platinum Pfx DNA polymerase 0.4 %l 
dH2O Up to volume 
TOT 50 %l 
 
Zero Blunt TOPO PCR Cloning (Invitrogen) was used for direct insertion of PCR 
products into a plasmid vector pCR-Blunt II-TOPO as followed: 
 
Reagent Volume 
Fresh PCR product 0.5 to 4 %l  
Salt solution 1 %l 
Water Add to a final volume of 5 %l 
pCRII-Blunt-TOPO vector 1 %l 
Final volume 6 %l 
 
After a 5 min incubation, 2 %l of TOPO Cloning product each were transformed 
into competent E.coli cells. Cells were plated on agar plates containing Kanamycin 
resistance gene carried by the plasmid. 
 
2.4.7. Site-directed mutagenesis  
 
Site-directed mutagenesis was performed using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene): 
- to replace Serine (tcc) with Glutamate (gag) to have S625E in the Cacnb2 
template: 
     SE Fw: 5’aacatgtggacgggtatggagcacaccgcga 
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             SE Rw:  5’tcgcggtgtgctccatacccgtccacatgtt 
- to replace Lysine (aaa) with Glutamine (caa) in the amino acidic sequence found 
to interact with Cav#2-SE . 
As template Cacnb2 wt and Cacnb2-SE were used to have the following 
mutations: K141Q, K149Q, K161Q and K149-161Q or SE-K141Q, SE-K149Q, 
SE-K161Q and SE-K149-1611Q. 
The mutagenic oligonucleotide primers that contained the desired mutation were: 
1) Lys 141 Fw: 5’gccatctccttcgaggccCaagattttctg 
      Lys 141 Rw: 5’cagaaaatcttgggcctcgaaggagatggc  
2) Lys 149 Fw: 5’catgttaaagaaCaatttaataatgactggtggatgga   
      Lys 149 Rw: 5’tcctatccaccagtcattattaaattgttctttaacatg     
3) Lys 161 Fw: 5’tggataggacggctggttCaagaaggctgtgaa   
      Lys 161 Rw: 5’ttcacagccttcttgaaccagccgtcctatcca 
The following PCR conditions were used: 
Mix Volume 
10X Reaction Buffer 5 %l 
dNTP mix 1 %l 
Quick solution 3 %l 
125 ng primer Fw x %l 
125 ng primer Rw x %l 
template DNA (10 ng) x %l 
PfuUltra HF DNA Polymerase 1 %l 
dH2O up to %l volume 
total volume 51 %l 
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The PCR reaction was performed by a DNA pre-denaturation for 1 min at 95°C 
and followed by 18 cycles of DNA denaturation at 95°C for 50 sec, primer 
annealing at 60°C for 50 sec and DNA extension at 68°C for 7 min. The reaction 
was maintained at 4°C after a final step of DNA extension at 68°C for 7 min. 
After addition of 1 %l of DpnI (10U/%l) at 37°C for 1 hour to digested the non-
mutated supercoiled dsDNA, XL10-Gold Ultracompetent cells were transformed 
with 2 %l of the DpnI-treated DNA following the manufacturer’s instruction. The 
mutated DNA was confirmed by DNA sequencing. 
 
2.5. Western blot analysis and Antibodies 
 
Proteins expression was evaluated in total lysates or cell fractions by Western blot 
analysis according to standard procedures. Samples were homogenized in RIPA 
buffer (150 mM NaCl, 10 mM Tris pH 7.2, 0.1 % SDS, 1% Triton-X100, 5 mM 
EDTA, 100 %M Na3VO4, 10 mM NaF, Protease inhibitor 1X (Thermo Fisher 
Scientific), loaded onto a 4-12% or 10-20% NuPAGE Tris-Glycine Gel, or 3-8% 
NuPAGE Tris-Acetate Gel (Invitrogen), separated by electrophoresis and 
trasferred to a PVDF membrane (Millipore). 
Antibodies against the following proteins were used: 
 
Primary antibodies Dilution Company 
Mouse anti CACNA1 1:500 Abcam 
Mouse anti DHPR Cav!1 1:500 Abcam 
Rabbit anti CACNB2 
Rabbit anti Cav"2 
1:500 
1:500 
Abcam 
Provided by Dr.Haase 
Rabbit anti PDK1 1:1000 EMD 
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Rabbit anti Akt pan, pAkt-
Thr308 
1:1000 Cell Signaling Technology 
Rb anti –phospho-
(Ser/Thr) Akt substrate 
(PAS) 
1:1000 Cell Signaling Technology 
Rabbit anti HA 1:500 Abcam 
Rabbit anti tubulin 1:2000 Novus Biological 
Rabbit anti GAPDH 1:2500 Cell Signaling Technology 
 
All protein levels were normalized to GAPDH or tubulin. Horseradish peroxidase-
conjugated secondary antibodies (Goat anti mouse and Goat anti rabbit-HRP, 
1:10000) and ECL (Thermo Fisher Scientific) were used for protein detection with 
GBox iChemi System (Syngene). Image J software (National Institutes of Health) 
was used to perform densitometry analysis. 
 
2.6. Pulse chase and immunoprecipitation experiments 
 
36 h post transfection, 293T cells were starved for 30 minutes in methionine- and 
cysteine-free DMEM medium (Sigma) and then were labeled for 30 minutes by 
adding 500 %Ci [35S]-L-methionine and 2 mM L-cysteine. Radioactive media was 
eventually washed out with PBS (time 0 pulse) and replaced with normal 
DMEM. Time points were at 4, 10 and 25 h post pulse. Labeled cells were then 
lysed in RIPA buffer, lysates incubated on ice for 30 min and centrifuged at 400 x 
g for 15 min. The supernatants (500 %g of protein) were eventually used for 
immunoprecipitation experiments with anti-GFP polyclonal IgG (GTX20290). 
Immunoprecipitates were separated on a 3-8% SDS–PAGE gel and exposed to X-
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ray film. Radioactivity was quantitated with ImageQuant 5.2 software (GE 
Healthcare). 
 
2.7. GST pull-down assay 
 
Affinity-purified GST fusion proteins were generated using pGEX system (GE 
Healthcare) and phosphorylated as described below. GST fusion protein bound to 
glutathione-Sepharose 4B beads (GE Healthcare) was incubated with 25 %l of 35S-
labeled Met with moderate shacking at 25 °C for 2 h in 200 %l of binding buffer 
containing 20 mM Hepes, pH 7.9, 1 mM EDTA, 10 % glycerol, 0.15 M KCl, 
0.05 % NP-40 and 1 mM DTT. 35S-labeled probes were generated from the C-
terminal region of Cav!1 cDNA fragments under control of the T7 promoter using 
the TnT Quick Coupled Reticulocyte Lysate System L1170, Promega), washed 
three times with washing buffer (20 mM Hepes, pH 7.9, 1 mM EDTA, 10 % 
glycerol, 250 mM KCl and 0.1 %NP-40) and centrifuged. Bound proteins were 
eluted in SDS sample buffer, subjected to SDS-PAGE and detected by 
autoradiography by incubation with recombinant Akt (Millipore). In brief, 5 %g 
GST-Cav!2 or GST beads were incubated at 30°C for 45 min in a 50 %l solution 
containing 2 %g activated kinase, 10 mM Hepes-KOH, pH 7.5, 50 mM $–
glycerophosphate, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MnCl2 and 1 mM 
ATP. 
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2.8. Yeast two hybrid screening 
 
2.8.1. Principle 
 
The yeast two-hybrid system (Y2H) can be used to identify novel protein 
interactions by screening cDNA libraries, to confirm suspected interactions and to 
define interacting domains. 
In the Y2H system a bait gene is expressed as a fusion to the Gal4-binding domain 
(DNA-BD), while libraries of prey proteins are expressed as fusions to the Gal4 
activation domain (AD; [99]). When bait and library (prey) fusion proteins 
interact, the DNA-BD and AD are brought into proximity to activate 
transcription of four independent reporter genes (AUR1-C, ADE2, HIS3 and 
MEL1) (Figure 14). 
 
 
Figure 14. The Yeast Two Hybrid system principle. 
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There are four integrated reporter genes under the control of three distinct Gal4-
responsive promoters (Figure 15): 
1) AUR1-C. A dominant mutant version of the AUR1 gene that encodes the 
enzyme inositol phosphoryl ceramide synthase. AUR1-C is expressed in 
Y2HGold Yeast Strain in response to protein-protein interactions that 
bring the GAL4 transcriptional activation and DNA binding domains into 
close proximity. In Saccharomyces cerevisiae, its expression confers 
strong resistance (AbAr) to the otherwise highly toxic drug Aureobasidin 
A. This drug reporter is preferable to nutritional reporters alone, due to 
lower background activity. 
2) HIS3. Y2HGold is unable to synthetize histidine and is therefore unable to 
grow on media that lack this essential amino acid. When bait and prey 
proteins interact, Gal4-responsive His 3 expression permits the cell to 
biosynthetize histidine and grow on –His minimal medium. 
3) ADE2. Y2HGold is also unable to grow on minimal media that does not 
contain adenine. However, when two proteins interact, Ade2 expression is 
activated, allowing these cells to grow on –Ade minimal medium. 
4) MEL1. MEL1 encodes !-galactosidase, an enzyme occurring naturally in 
many yeast strains. As a result of two-hybrid interactions, !-galactosidase 
(MEL1) is expressed and secreted by the yeast cells. Yeast colonies that 
express Mel1 turn blue in the presence of the chromagenic substrate X-! -
gal.  
Three  promoters controlling the four reporter genes AUR1-C, HIS3, ADE2 and 
MEL1 in Y2HGold are unrelated except for the short protein binding sites in the 
UAS region that are specifically bound by the Gal4 DNA-BD. Thus, library 
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proteins that interact with unrelated sequences flanking or within the UAS (i.e., 
false positives) are automatically screened out. 
 
Figura 15. Reporter gene constructs in Matchmaker yeast strains. In Y2HGold, the HIS3, ADE2 and MEL1/AUR1-C 
reporter genes are under the control of three completely heterologous Gal4-responsive promoter elements-G1, G2 and M1, 
respectively. The protein-binding sites within the promoters are different, although each is related to the 17-mer consensus 
sequence recognized by Gal4. 
 
After cotransformations of the bait and the prey plasmids into the yeast host 
strain, the transformants are plated on minimal medium lacking Leu, Trp, His and 
Ade to select for those clones that contain both types of plasmid (i.e, Leu+, 
Trp+,His+, Ade+). To further eliminate false positives, candidates prey plasmids 
are tested for reporter gene activation when cotransformed into yeast cells in 
combination with the bait vector (without insert), the bait plasmid and an 
unrelated bait plasmid with an unrelated noninteracting protein.  
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2.8.2. Procedure 
2.8.2.1. Cloning and screening  
Cacnb2-wt and Cacnb2-SE cDNAs were used to perform Y2H screens. Amplified 
PCR product were cloned in frame into the pGBKT7 vector to obtain GAL4 
DNA-BD fusion. (In-Fusion Advantage PCR Cloning kit, Clontech). The 
following PCR conditions were used: 
Mix Volume 
10X Pfx Amplification Buffer 5 µl 
10 mM dNTP mixture 1.5 µl 
50 mM MgSO4 1 µl 
Primer mix (10 µM) 1.5 µl 
Template DNA (200 ng) x µl 
Platinum Pfx DNA Polymerase 0.4 µl 
dH20 Up to volume 
TOT 50 µl 
 
The PCR reaction was performed by a DNA pre-denaturation for 5 min at 94°C 
and followed by 5 cycles of DNA denaturation at 94°C for 30 sec, primer 
annealing at 56°C for 30 sec and DNA extension at 72°C for 1 min and by 25 
cycles of DNA denaturation at 94°C for 30 sec and DNA extension at 72°C for 2 
min. The reaction was maintained at 4°C after a final step of DNA extension at 
72°C for 10 min. 
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PCR primers were designed that share 16 bp of homology with the sequence at 
the ends of the linearized vector pGBKT7 (in order to keep the BamHI and EcoRI 
sites intact) and 24 bp homology to our bait (Cacnb2-wt and -SE): 
1) beta 2 Fw: 5’catggaggccgaattc gtcccaaagcgacacgtccaagtcg 
2) beta 2 Rw: 5’gcaggtcgacggatcc ctcgccagcctcattccttctctt 
After obtaining pure PCR product with a single specific band and no background, 
the PCR product was treated with DpnI per 1 h at 37°C and Spin-column purified 
with Wizard SV PCR clean-up system (Promega) following manifacturer’s 
instructions. 
Then purified PCR insert and vector together at a 2:1 molar ratio were mixed as 
follows in the In-Fusion cloning reaction: 
MIX VOLUME 
5X In-fusion reaction buffer 2 %l 
In-Fusion Enzyme 1 %l 
Vector pGBKT7 x %l 
Purified PCR insert (b2 wt or SE) x %l 
H2O (as needed) x %l 
Total volume 10 %l 
 
  
The reaction was incubated for 15 min at 37°C, followed by 15 min at 50°C, then 
placed on ice. The reaction volume was brought up to 50 %l with TE buffer, pH 8 
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and mixed well. Competent E.coli cells were transformed with 2.5 %l of the diluted 
In-Fusion reaction mixture, following the transformation protocol. Each 
transformation reaction was spread on LB plate containing the appropriate 
antibiotic and incubated overnight at 37°C. The next day, isolated colonies were 
picked and plasmid DNA was isolated with the standard method of Wizard Plus 
SV Miniprep  (Promega), according to the manufacturer’s instruction. To 
determine the presence of insert, DNA was checked by sequencing. For screening, 
bait constructs were transformed into Saccharomyces cerevisiae, strain Y2HGold 
(Matchmaker Gold Yeast Two-Hybrid System, Clontech). Subsequently, cells 
were transformed with either human or mouse heart cDNA expression libraries in 
the pGADT7-Rec prey vector (Mate & Plate Libraries, Clontech). 
 
2.8.2.2. Transformation of bait plasmid 
 
5 ml of synthetic dropout (SD) medium was inoculated with the bait yeast strain 
Y2HGold and grown overnight at 30°C with maximal shaking. The following 
morning, OD600 was measured and 50 ml of YPD was inoculated with 2.5x10
8 
cells ~ 5x106 cells/ml (OD600  ~ 3x10
7 cells/ml). After 3-4 hours of incubation with 
maximal shaking until the cell titer reached 2x107 cells/ml, cells were harvested by 
centrifugation at 3000g for 5 min. Cells were washed with H2O and 0.1 M LiAc 
and after completely removing the H2O, the following components from the 
YeastMaker Yeast Transformation System 2 (Clontech) were added in the given 
order : 
- 2.4 ml 50% PEG  
- 360 %l 0.1 M LiAc  
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- 50 %l 10 mg/ml Herring testis carrier DNA  
- 1.05 ml H2O 
After vigorously shaking, 400 %l of transformation mixture were added to each 
transformation tube containing 1 %g of each plasmid: 
1) Bait plasmid (pGBKT7+ beta 2 SE)                               plated on -T 
2) Bait plasmid (pGBKT7+ beta 2 SE) + library plasmid  plated on –TL or -
TL/X-!-gal 
3) Bait plasmid (pGBKT7+ beta 2 SE) + library plasmid  plated on –HTLA/ -
HTLA/AbAr/ X-!-gal 
After incubation at 30°C for 30 min, reactions were incubated at 42°C for 30 min 
and subsequently cooled in ice-water. 1 ml of water was added to each tube and 
the cells were collected by centrifugation. Cells were resuspended in 100 %l of 
water and plated on SD-plates lacking the amino acids Trp-, Leu- and/or His-Ade-. 
Plates were incubated at 30°C until colonies appeared (~5 days). Transformation 
2) showed the transformation frequency, while transformation 3) was used to test 
if the bait was autoactivating, i.e. could activate the expression of the reporter gene 
in the absence of the GAL4 binding domain. Typically, no colonies should grow 
on this plate. 
 
2.8.2.3. Transformation of the yeast strain containing the bait plasmid plasmid 
with the chosen library 
 
50 ml of SD- Trp-  medium was incubated with bait containing yeast colonies and 
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incubated overnight at 30°C with maximal shaking. As described above, cells were 
diluted at 5x106 cells/ml in 150 ml of YPDA and incubated for approximately 4.5 
h until the cell titer reached 2x107 cells/ml. Cells were harvested and pooled , 
washed with water and 0.1 M LiAc and the following component from the 
YeastMaker Yeast Transformation System 2 were added: 
- 7.2 ml 50% PEG  
- 1.08 %l 0.1 M LiAc  
- 150 %l 10 mg/ml Herring testis carrier DNA 
- 30 %g of library plasmid DNA (pGADT7-Rec, Matchmaker, Clontech) 
- 2.1 ml H2O 
After vigorously mixing, the transformation mixture was incubated for 30 min at 
30°C shaking, then for 30 min at 42°C and subsequently cooled in ice. Cells were 
collected by centrifugation,  then resuspended in 10 ml of water and plated out on 
50 large 150 mm SD-TL/AbAr/ X-!-gal. Plates were incubated at 30°C for up to 7 
days until colonies appeared. Colonies  were picked, restreaked onto higher 
stringency SD-HTLA/AbAr/ X-!-gal plates.  
To eliminate any positive colonies containing the Cav!1 constructs,  yeast colony 
PCR was performed with oligos designed to recognize the AID domain (Cav ! 1 
interaction domain):  
- AID Fw: 5’ tcacggtgttccagtgcatcacc     
- AID Rw: 5’ atcactcaggccgaagacatcga 
The PCR reaction was performed by a DNA pre-denaturation for 5 min at 94°C 
and followed by 30 cycles of DNA denaturation at 94°C for 30 sec, primer 
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annealing at 60°C for 30 sec and DNA extension at 72°C for 1 min.The reaction 
was maintained at 4°C after a final step of DNA extension at 72°C for 10 min. 
 
The remaining library plasmids from yeast were rescued using the Easy Yeast 
Plasmid Isolation Kit (Clontech), following the manufacturer’s instructions. 
Plasmids were transformed into E.coli, the DNA was  purified and then sequenced 
using a standard T7 primer. 
  
Colonies were re-transformed into yeast with either the bait or the prey vector 
using the transformation protocol that was used for the initial test of the bait 
plasmid (transformation of bait plasmid), to confirm that the positive interactions 
are genuine: 
1) bait + candidate prey plated on SD-LT/X-!-gal and SD-HTLA/AbAr/ X-
!-gal plates (blue colonies expected) 
2) empty pGBKT7 + candidate prey plated on SD-LT/ X-!-gal (white 
colonies expected) and SD-HTLA/AbAr/ X-!-gal plates (no expected 
colonies) 
Co-Immunoprecipitation assay from mammalian cell extracts (transfected 293T 
cells) allowed to identify and double-confirm true physical interaction between the 
bait cloned in plasmid pXJ40-cMyc (pXJ40-cMyc beta2-SE) and the preys 
cloned in the plasmid pXJ40-HA (pXJ40-HA Ms or H prey). 
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2.9. Statistical Analysis  
 
Statistical comparison was performed within at least three independent 
experiments by paired or unpaired Student’s t-test, whereas comparison between 
groups was analyzed by one-way repeated-measures analysis of variance 
(ANOVA) combined with a Newman-Keuls post-test to compare different values 
using Prism 4.0 software (GraphPad Software, CA). Differences with P<0.05 
were considered statistically significant. 
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3. RESULTS 
 
3.1. Characterization of mice lacking PDK1 expression 
 
To gain insight into the mechanism of action by which Akt regulates ICa,L and Ca
2+ 
handling in the heart, we studied a mouse line with tamoxifen-inducible [97] and 
cardiac-specific deletion of PDK1, the upstream activator of all three Akt 
isoforms.  Mice in which exons 3 and 4 of the pdk1 gene were flanked by loxP 
excision sequences [100] were crossed with transgenic (Tg) mice expressing an 
inducible and cardiac-specific MerCreMer !-MHC promoter driving the cre 
recombinase gene [97], resulting in MerCreMer !-MHC PDK1 mice (KO). 
Similar to the muscle creatine kinase-Cre PDK1 mouse model [100], PDK1 gene 
deletion in the adult mouse heart  (KO) (Figure 16A) resulted in a lethal 
phenotype with a mortality that reached 100% at 10 days after tamoxifen 
injection (Figure 16B) [101]. 
Age-matched littermate control mice without cre (wildtype (WT)) were unaffected 
by tamoxifen treatment. Consistent with findings from the previously reported 
analysis of the PDK1 KO mouse model [100], cardiac function evaluated by 
echocardiography at 7 days after tamoxifen injection, revealed dramatically 
impaired systolic function with severe dilated cardiomyopathy and an abrupt 
drop in fractional shortening in KO, but not in WT mice (Figure 16C). Histological 
examination substantiated the echocardiographic findings, revealing significant 
dilatation of both ventricles and atria (Figure 16D) [101].  
These observations indicate that PDK1/Akt activity plays a major role in 
maintaining adult heart function.  
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Figure 16. Characterization of  mice lacking PDK1 expression. A) PDK1 protein and RNA levels assessed by western 
blot (top) and RT-PCR (bottom) analysis of atria and left (LV) and right (RV) ventricular CMCs from WT and KO mice. 
Protein and RNA loading were normalized to GAPDH levels. B) Survival curve for mice lacking PDK1 (KO) in the 
heart. Mortality begins 5 d after tamoxifen injection and reaches 100% by day 10 after the beginning of the treatment. 
Time point of tamoxifen injections (hash marks) and echocardiography analysis (arrows) are shown (n=10). C) 
Echocardiographic (M mode) assessment of  LV size and function. Left ventricular diastolic internal dimensions (red 
lines) and Left ventricular  systolic internal dimensions (blue lines) were increased in ko mice. Heart rates were 486 
bpm and 511 bpm in the wt and the ko hearts, respectively. D) Ematoxylin- and eosin-stained paraffin sections show 
severe dilatation and thinning of ko hearts.  
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3.2. Deficiency in Akt activity leads to a reduction in the Cav"1 protein level 
 
Using this cardiac specific PDK1 knockout mouse model, we investigated whether 
deficiency in Akt activity results in changes in expression or activation of signaling 
molecules that are implicated in Ca2+ handling and cardiac function. Western blot 
analysis of extracts from WT and KO mouse ventricle revealed striking changes in 
protein expression upon induction of the PDK1 knockout (Figure 17A-B). 
Notably, KO mice had decreased protein levels of the pore-forming Ca2+ channel 
subunit (Cav!1), which progressed as PDK1 protein expression gradually 
declined. No change in the protein level of the regulatory Cav!2 subunit was 
observed. As PDK1 expression decayed, levels of Akt activation also dramatically 
decreased (assessed by phosphorylation of Akt at the PDK1 phosphorylation 
site, Thr308), despite unaltered expression of total Akt protein (Figure 17A-B). 
Based on this evidence, we decided to perform further experiments by day 6 after 
the beginning of treatment. 
Although the main physiological action of PDK1 is on Akt activation, PDK1 can 
potentially influence other members of the cAMP-dependent, cGMP-dependent 
and protein kinase C (AGC) kinase protein family, such as PKC and PKA, which 
could also affect the cellular Ca2+ handling [96, 102]. However, PKC activity was 
unchanged, no apparent effect of PDK1 deletion on SERCA2a as well as PKA 
activity because the phosphorylation of specific PKA regulatory sites in two SR 
Ca2+-regulatory proteins, ryanodine receptor (Ryr2-P2809) and phospholamban 
(PLN; PLN-P16) were unchanged in KO mice [101]. 
Taken together, these data suggest that an acute reduction in Akt activation affects 
expression of proteins involved in the Ca2+ influx through the cell. 
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Figure 17. Alteration of Ca
2+
 handling proteins in PDK1 KO CMCs. A) Western blot and B) densitometric analysis of 
ventricular homogenates along a time course of tamoxifen inductions (day 1-6 treatment is indicated by the line in A) 
using various antibodies. A representative experiment is shown (n=3). Error bars show SD.  
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3.3. Deficiency in Akt activity affects ICa,L  
 
Ca
2+
 handling and inotropism were examined in adult cardiomyocytes freshly 
isolated from WT and KO mice. Using the whole-cell voltage-clamp technique, we 
recorded and analyzed LTCC ICa,L properties. No difference in cell size was 
observed between WT and KO cells as deduced from membrane capacitance (Mc) 
measurements. Mc was 116±6 pF in WT cells (n=18) and 115±6 pF in KO cells 
(n=18). However, the density of ICa,L (pA/pF) was decreased in KO vs. WT 
(Figure 18B). At 0 mV, density of ICa,L was -9.08±0.96 pA/pF in KO cells (n=12) 
vs. -16.26±0.96 pA/pF in WT cells (n=12; p<0.001). In addition, there was no 
significant difference in either steady-state activation or inactivation curves (data 
not shown). Indeed, mean half activation occurred at -12.97±0.53 mV in WT cells 
vs. -15.07±0.66 mV in KO cells and mean half inactivation occurred at -
31.11±0.48 mV in WT cells vs. -30.77±0.42 mV in KO cells. The absence of a 
shift in the voltage-dependence of these properties (Figure 18B) was consistent 
with the absence of modification in gating properties of the LTCC, suggesting that 
a reduction in the number of functional LTCCs can account for the observed 
decrease in ICa,L in KO mice. Of note, the decay kinetics of ICa,L was slower in KO 
cells compared to WT cells with a decrease in the early fast inactivating 
component (Figure 18A). Consistent with previous observations by us and others 
regarding the role of Akt in cardiac function [15, 47, 49, 103], contraction (Figure 
18C) and systolic Ca2+ amplitudes (Ca2+ transients) (Figure 18D) were 
significantly depressed (by ~35% and 30%, respectively, P<0.05) in KO 
cardiomyocytes compared to WT littermates.  
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Figure 18. Impaired intracellular Ca2+ handling and contractility in PDK1 KO CMCs. (A and B) Smaller Ca2+ current in 
KO CMCs. A) Whole cell representative ICa,L currents normalized for difference in cell size. B) ICa,L I-V current/voltage 
relationships (n=12; *, P < 0.05; **, P<0.01). C and D) CMC contraction and Ca
2+
 shortening is decreased in KO 
compared with WT CMCs (*, P<0.05; ANOVA). Error bars show SEM. 
 
The observed reduction cardiac contractility could be explained by reduced Ca2+ 
entry into cells via the LTCC, but decreased intracellular Ca2+ release from the 
sarcoplasmic reticulum (SR) may also contribute. This is consistent with the 
observed slowing of the early fast inactivation of ICa,L (Figure 18A), which is 
highly dependent on CICR-triggered SR Ca2+ release during the action potential 
[52]. Therefore, we conclude that the reduced ICa,L may contribute to the reduced 
contractility in KO hearts.  
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3.4. Akt regulates the Cav"1 protein level at the plasma membrane 
 
The properties of the Cav!1 subunit are known to be markedly affected by LTCC 
accessory subunits [61, 104]. Among the LTCC accessory subunits expressed in 
the heart, Cav!2 is known to act as a chaperone for the Cav!1 subunit, both as a 
positive modulator of channel opening probability and for its trafficking from the 
endoplasmic reticulum (ER) to the plasma membrane [105, 106]. Because Cav!2 is 
the only LTCC accessory subunit containing an Akt-phosphorylation consensus 
site [105], we hypothesized that Cav!2 might lose this chaperone activity in the 
absence of Akt-induced phosphorylation, resulting in Cav!1 protein degradation. 
In support of this hypothesis, forced expression of the active E40K-Akt mutant 
restored Cav!1 protein levels in isolated cardiomyocytes from KO mice (Figure 
19A). Similarly, cardiomyocytes from transgenic mice expressing constitutively 
active HA-E40K-Akt (Tg Akt) [15] showed increased Cav!1 levels compared to 
WT controls (Figure 19B).  
 
   
 
Figure 19. Akt mediates regulation of Cav!1 protein density at the plasma membrane. Cav!1 protein levels in KO CMCs 
infected with empty (mock) or active E40K-Akt (AdAkt) expressing adenoviral vector (A) and in whole lysates of WT 
and E40K-Akt (Tg Akt) hearts (B). 
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3.5. Akt is determinant for Cav"1 protein level regulation by direct 
phosphorylation of the Cav!2 chaperone-subunit 
 
To assess whether Akt is directly involved in modulation of Cav!2 chaperone 
activity in the heart, we first confirmed the interaction between Akt and Cav!2. 
Ventricular homogenates derived from either WT or Tg Akt mice were 
immunoprecipitated with anti-HA antibody and assayed for Cav!2, which revealed 
association of the Cav!2  subunit with active Akt (Figure 20A).  
To determine whether Cav!2 can be phosphorylated by Akt, Cav!2-
immunoprecipitates from cardiac homogenates were incubated with recombinant 
active Akt and [$-32P]ATP. A band corresponding to phosphorylated Cav!2 was 
detected only in the presence of the kinase (Figure 20B, left).  
 
 
 
Figure 20. Akt interacts with and phosphorylates Cav!2. A) Coimmunoprecipitation assay of Akt and Cav!2. Ventricular 
homogenates from WT and HA-E40K-Akt Tg mice (Tg Akt) immunoprecipitated with antibodies against HA and 
immunoblotted for Cav!2 as well as HA as a control. B) Examination of Cav!2 phosphorylation by Akt. In vitro kinase 
assays were performed with immunoprecipitation Cav!2 incubated with recombinant active Akt and 
32
P-labeled ATP 
(left) or immunoprecipitated Cav!2 from WT and KO cardiac extracts from mice treated or not treated with 1 mU/g 
insulin using phospho-Akt substrate (PAS) antibody (right). 
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To determine whether the Cav!2 subunit was phosphorylated by Akt in vivo, we 
treated overnight-starved mice with 1 mU/g insulin, which causes activation of 
Akt [107]. 20 min post treatment, Cav!2 was immunoprecipitated from ventricular 
homogenates, subjected to Western blot analysis and probed for phosphorylated 
Akt consensus sites using PAS (Phospho-Akt Substrate) antibody. This revealed 
insulin-stimulated phosphorylation of Cav!2 in WT but not in KO hearts (Figure 
20B, right). Taken together, these data demonstrate that Akt binds to and 
phosphorylates Cav!2, the chaperone for Cav!1.  
To directly assess whether Akt phosphorylation of Cav!2 protects Cav!1 from 
protein degradation, we constructed a mutant of Cav!2, in which the Serine 
contained in the putative Akt-consensus site (R-X-X-R-S/T) was replaced by 
Glutamate (Cav!2-SE) to mimic phosphorylation. Cotransfection of 293T cells 
with CaV!1 and Cav!2-SE resulted in CaV!1 protein levels that were increased 
compared to those found when cotransfected with Cav!2-WT (Figure 21A). 
Similarly, CaV!1 expression was increased in insulin treated Cav!2-WT 
cotransfected cells (Figure 20A). Notably, the active phosphomimic Cav!2-SE also 
counteracted the downregulation of CaV!1 induced by an Akt inhibitor (Figure 
21B).  
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Figure 21. Akt phosphorylation of Cav!2 protects Cav!1 from protein degradation. A) YFP- Cav!1- cotransfected 293T 
cells with the mutant variant Cav!2-SE. Cells were serum starved overnight and treated with 100 %M insulin (A) or 5 %M 
Akt inhibitor (Akt inh (B) as indicated. The expression of YFP- Cav!1 in lysates was monitored by western blot analysis 
with anti-YFP antibody and normalized as assed on transfection efficiency (Cav!2) and protein amount (tubulin; n=3). 
 
To support the evidence that Akt-dependent phosphorylation of Cav!2 is 
determinant for Cav!1 stability and functionality, we measured the effect of the 
Cav!2-SE mutant on Ca
2+ current. While cotransfection of cells with Cav!1 and 
Cav!2-WT resulted in significant depressed ICa,L in serum-free medium compared 
to serum-containing medium where Akt is phosphorylated, cotransfection of 
Cav!1 and Cav!2-SE mutant completely counteracted this reduction (Figure 22A-
B).  
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Figure 22. Akt phosphorylation of Cav!2 preserves Cav!1 currents. A) Ca
2+
currents recorded in co-transfected 293T 
cells with YFP- Cav!1 and Cav!2-WT or Cav!2-SE mutant cultivated for 36 h in the presence or absence of 10% FBS. B) 
Representative current traces are shown. n> 35 at each condition (*, P< 0.05 compared with YFP- Cav!1; ANOVA). 
Error bars show SEM. 
 
3.6. Akt regulates Cav!1 protein stability 
 
PEST sequences have been suggested to serve as signals for rapid proteolytic 
degradation through the cell quality control system [108-111]. Notably, PEST-
mediated protein degradation has recently been suggested to play an essential role 
in modulating neuronal Ca2+ channel function through regulation of the Cav!3 
accessory subunit [111]. Our findings raise the possibility that processing of the 
Cav!1 protein may be affected in a similar way. To test this hypothesis, we used 
the web-based algorithm PESTFind {Rogers, 1986 #1198} in a search for 
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potential Cav!1 PEST sequences and found several putative motifs (aa 435-460; 
807-820; 847-858; 1732-1745; 1839-1865). Intriguingly, the highest-scored 
potential PEST sequences obtained are highly conserved among species (Table 5), 
with one located in the I–II linker of the CaV!1 subunit and overlapping with the 
!1-interacting domain (AID), the primary binding region for CaV!2 [58].  
 
 
 
Table 5. PEST sequences are highly conserved in CaV!1. Occurrence of PEST sites within the amino acid sequence of 
CaV!1 from the mouse, rat and human. Amino acid identity is underlined. 
 
To determine whether these PEST sequences are involved in Cav!1 degradation 
control, we generated two in-frame deletion mutants encompassing either the I-II 
(Cav!1-'P) or II-III (Cav!1-'H) cytosolic linker region (Figure 22A). A pulse-
chase analysis, with a chase starting 36 h post-cell starvation, revealed that both 
Cav!1-'P and Cav!1-'H exhibited markedly increased protein stability compared 
to Cav!1-WT (Figure 22C). In particular, Cav!1-WT showed a short half-life 
typical of proteins containing PEST sequences [112] with a rapid and progressive 
degradation starting 4 h from the chase and reaching 50% of degradation 25 h after 
the chase. In contrast, Cav!1-'P and Cav!1-'H mutants were less sensitive to 
degradation and were degraded by only 23% and 15% after 25 h, respectively 
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(P<0.001). Notably, cotransfection of Cav!2-SE with Cav!1-WT resulted in a 
considerable increase in the half-life of Cav!1-WT (Figure 22C). 
 
 
 
 
 
 
Figure 23. Rapid protein degradation PEST sequences determine Cav!1 protein instability. A) Schematic representation 
of Cav!1 mapping the AID and PEST sequences in the I-II and II-III cytosolic loops. Deleted PEST sequences (P and H) 
are highlighted in red. B) Half-lives of WT Cav!1 subunit (alone or cotransfected with Cav!2-SE) and its in-frame 
'PEST mutants (Cav!1-'H and Cav!1-'P) were determined in 293T cells. After ON starvation, transfected cells were 
pulse chased and analyzed along a time course (*, P<0.001 compared with Cav!1; ANOVA; n=3). C) The Cav!1C 
terminus interacts with the Akt phosphorylated GST- Cav!2 coiled-coil region. D) ICa,L recorded in 293T cells 
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cotransfected with Cav!2-WT or either Cav!1-WT or Cav!1-'H and cultivated for 36 h in presence or absence of 
10%FBS. 
 
Notably, direct interaction took place between the Akt-phosphorylated Cav!2 C-
terminal coiled-coil region and the Cav!1 C-terminal domain (Figure 23C). No 
interaction was found with other Cav!1 cytosolic domains, although it cannot be 
excluded that other binding sites may exist. 
To assess whether PEST-deleted Cav!1 channels are still functional, traffic 
appropriately to the membrane and associate with the Cav!2 subunit, we measured 
Ca2+ current in Cav!1-'H mutant-transfected cells. No significant differences in 
ICa,L were found in cells transfected with Cav!1-WT compared to Cav!1-'H. 
Conversely, although serum deprivation resulted in ICa,L reduction in Cav!1-WT 
transfected cells, no significant changes were observed in Cav!1-'H mutant-
transfected cells (Figure 23D). Current densities (pA/pF) were normalized to the 
control condition and n >35 at each condition (*, P<0.05 compared with 
Cav!1;ANOVA). This confirms that PEST-deleted Cav!1-'H is resistant to rapid 
protein degradation and maintains its integrity and physiological function. 
Taken together, our results suggest that Akt-mediated phosphorylation of Cav!2 
C-terminal coiled coil regulates Cav!1 density through protection of Cav!1 PEST 
motifs from the cell protein degradation machinery. Impairment of this mechanism 
is expected to result in dysregulation of cardiomyocyte contractile function . 
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3.7. Akt-phosphomimetic Cav!2 constructs mediate LTCC density 
 
To search for potential Akt-phosphomimetic constructs active on LTCC density 
control, we cloned three different nucleotides sequences encoding either the whole 
CaV!2 terminal coiled coil region (Cav!2-XB, 194 aa) or two shortest sequences 
(Cav!2-XX of 91 aa and Cav!2-Akt of 36 aa) encompassing the Akt consensus site 
above identified (Figure 24). CaV!2 wt and Cav!2-SE cDNAs were used as 
templates.  
 
Figure 24. Identification of potential Akt-phosphomimetic constructs active on LTCC density control: the Cav!2-wt  
control (Cav!2-XB, Cav!2-XX, Cav!2-Akt) and the phosphomimetic Cav!2-constructs (Cav!2-SE-XB, Cav!2-SE-XX, 
Cav!2-SE-Akt). 
 
First, to determine the effect of Akt-phosphomimetic constructs effect on Cav!1 
protein stability, each Cav#2 wt control (Cav#2-XB, Cav#2-XX or Cav#2-Akt) or 
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phosphomimetic-#2 construct (Cav#2-SE-XB, Cav#2-SE-XX or Cav#2-SE-Akt) 
was cotransfected in 293T cells together with plasmids encoding Cav!1 and 
CaV#2. Western blot analysis showed that upon serum removal, both Cav#2-SE-
XB and Cav#2-SE-XX were able to maintain Cav!1 protein levels when compared 
to WT conditions. A mild effect was found with the shortest Cav#2-SE Akt 
(Figure 25A).  
 
 
 
Figure 25. Akt phosphomimetic constructs effect on Cav!1 protein stability. A) Western blot analysis in 293T cells 
cotransfected with each Cav#2-wt control (Cav#2-XB, Cav#2-XX or Cav#2-Akt) o or Akt-phosphomimetic Cav#2-
constructs (Cav#2-SE-XB, Cav#2-SE-XX or Cav#2-SE-Akt) for monitoring Cav!1 levels. Protein levels were normalized 
to GAPDH. B) Western blot analysis in 293T cells cotransfected with different concentrations of Cav#2 -wt or Cav#2 –SE 
constructs. Protein levels were normalized to GAPDH. 
  86 
 
Recently, oligomerization of Cav#2 subunits has recently been suggested to play 
an essential role in modulating Ca2+ channel function [113]. Therefore, to evaluate 
the presence of  any possible effect of Cav!1:#2-peptide stoichiometric on Cav!1 
stability, an increasing molar ratio of Cav!1:#2-peptide was used. Results showed 
the 1:2 ratio to be the optimal condition (Figure 25B). Based on this evidence, we 
decided to perform further experiments with this experimental setting. 
To establish whether the effect of the phosphomimetic Cav#2-SE constructs on 
Cav!1 protein leads to an increased stability of pore subunits that are also 
functional, ICa,L  was measured in 293T cells cotransfected with each construct. 
While cotransfection of cells with Cav!1 and Cav!2-WT resulted in significant 
depressed ICa,L in serum-free medium (3,06 ± 0,82 pA/pF, n=11) compared to 
serum-containing medium (5,08 ± 1,86 pA/pF, n=9) where Akt is 
phosphorylated, cotransfection of Cav!1 and each of Cav#2-SE-XB, Cav#2-SE-
XX, or Cav#2-SE-Akt constructs led to a significant counteract effect on ICa,L. In 
particular, remarkable increase of ICa,L was found when cells were cotransfected 
with Cav#2-SE-XB (4,21 ± 0,88 pA/pF, n=17). Similarly but to a lesser extent, 
ICa,L increased in cells cotransfected with Cav#2-SE-XX (3,2 ± 0,7 pA/pF, n=12), 
while no increase was found with Cav#2-SE-Akt  (1,91 ± 0,65 pA/pF, n= 9) 
(Figure 26A). 
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Figure 26. Cav#2-SE constructs lead to stable as well as functional Cav!1 protein. A) ICa,L measurement in 293T cells 
cotransfected with each Cav#2-SE-XB, Cav#2-SE-XX, or Cav#2-SE-Akt together with plasmids encoding Cav!1 + Cav# 2 
cultivated for 36 h in presence or absence of 10% FBS. B) Fluorescent-based calcium assay for analyzing changes in 
intracellular calcium flux in cells cotransfected with each Cav#2-SE-XB, Cav#2-SE-XX, or Cav#2-SE-Akt together with 
plasmids encoding Cav!1 + Cav#2 cultivated for 48 h in presence or absence of 10% FBS. (*, P< 0.05 compared with 
Cav!2 w/o serum condition; ANOVA). BayK8644 (1 %M) was used for LTCC activation. Here a representative 
experiment is shown (n=4). Error bars show SEM. 
 
Finally, to further validate the effect of these constructs on Cav!1 protein stability 
and function, a fluorescence-based calcium assay was used for analyzing changes 
in LTCC-mediated intracellular calcium flux. While cotransfection of cells with 
Cav!1 and Cav!2-WT determined a calcium flux reduction upon serum removal, a 
significant increase of calcium flux (!32% ,*, P<0.05) was found when cells were 
cotransfected with Cav#2-SE-XB, Cav#2-SE-XX or Cav#2 -SE-Akt constructs 
together with plasmids coding for Cav!1 with Cav#2. 
In conclusion, the three Akt-phosphomimetic constructs (Cav#2-SE-XB, Cav#2-
SE-XX, or Cav#2-SE-Akt) resulted with protective action toward Cav!1 protein 
stability and function.  
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3.8. Akt-phosphorylated Cav#2 C-terminal tail interacts with the globular domain 
of the Cav#2  
 
A yeast two-hybrid system approach was employed to establish whether the 
Akt-dependent phosphorylation of CaV#2 might be a trigger for the recruitment of 
other protein interacting partners involved in Cav!1 protein stability modification. 
CaV#2-SE (bait) was screened versus both adult human and mouse heart cDNA 
expression libraries (preys). 11 and 91 positive clones were obtained from human 
and mouse libraries, respectively. To exclude any clones corresponding to Cav!1, 
the main interactor of Cav #2,  yeast colony PCR was performed with oligos 
designed to recognize the AID domain (Cav!1 interaction domain). 7 and 22 Cav !1 
clones were obtained from the human and mouse colonies, respectively, and thus 
discarded. The remaining clones were subjected to DNA isolation, sequencing and 
classification as shown in Table 6. Surprisingly, 1 (human) and 3 (mouse) clones 
resulted with an aminoacid sequence 
(ISFEAKDFLHVKEKFNNDWWIGRLVKEGCEI) that corresponds to the 
globular region of the Cav #2 bait itself. 
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Table 6. Potential interactors of the bait CaV#2-SE obtained in the human and mouse heart library, respectively. They 
were classified as i) of  potential interest and ii) false positive (mithocondrial proteins, ATP synthase, 28rRNA, NADH 
dehydrogenase, HSP16). 
 
Retransformation of yeast cells with the CaV#2-SE bait and CaV#2 preys 
confirmed an interaction that was similar in intensity to a positive control 
consisting of a p53 bait with a large T-antigen prey. However, no interaction was 
found when the same preys were cotransformed with CaV#2 WT bait, thus 
corroborating the presence of a mechanism of action that rely on Akt-dependent 
phosphorylation (Figure 27).  
 
Figure 27. Validation in yeast of the interaction of the human (H79) and mouse (Ms81) candidate preys with CaV!2-SE 
bait after cotransformation. No colonies were obtained when the same preys were cotransformed with CaV#2 wt bait. 
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Subsequently, co-immunoprecipitation of either CaV#2-mouse or CaV#2-human 
from lysates of cotransfected cells with either these two proteins also pulled 
down CaV#2-SE (data not shown). 
Sequence overlapping of the 3 mouse sequences (Seq.1-3) and 1 human sequence 
(Seq.4) obtained, identified a minimal common region of interaction with the 
CaV#2-SE bait (in bold in Figure 28A). We named this minimal region as Tail 
Interacting Domain (TID). 
 
 
Figure 28. A) Sequence overlapping of the 3 mouse sequences (Seq.1-3) and 1 human sequence (Seq.4) identified a 
minimal common region of interaction with the CaV#2-SE bait (in bold). Sequence 1 (136-166 aa), Sequence 2 (136-275 
aa),  Sequence 3 (136-279 aa), Sequence 4 (136-275 aa). B) Structure of Cav #2 subunit: the globular domain, the coiled-
coil region and the sequences obtained in the Y2H screening.  
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Evaluation of the Cav#2  3D protein structure showed that TID sequence lyes in a  
solvent exposed cleft of the globular domain and thus accessible to potential 
protein-protein interaction (Figure 29). Intriguingly, in line with this and with the 
hypothesis that the interaction of the Akt-phosphorylated tail (negatively 
charged) might relay on accessible positively charged aminoacids, 3 Lysines 
(K141, K149, K161) were identified in the TID sequence 
(ISFEAKDFLHVKEKFNNDWWIGRLVKEGCEI).  
 
Figure 29. CaV#2 (Cacnb2) amino acidic sequence (655 aa). A) The globular portion is 1-460 aa, the coiled-coil region 
is highlighted in light blue (461-655 aa), the Akt consensus site in yellow (500-504 aa), the minimal sequence (136-166 
aa) found to interact with CaV#2-SE bait in our Y2H screening in red and the other sequences (136-275 aa) in green and 
(136-279 aa) in orange, respectively. The Lysines (K) identified and then mutated are highlighted in grey. B) Evaluation 
of the Cav #2  3D structure. The globular domain is shown in red, while the 3 Lysines found to be exposed to solvent and 
accessible to protein-protein interaction in yellow (from www.phosphosite.org). 
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To investigate the role of these accessible aminoacids in the proposed interaction 
process, site-specific mutagenesis of each positively charged Lysine with the 
neutral charged glutamine (K141Q, K149Q, K161Q) was performed. 
Interestingly, western blotting analysis derived from cells cotransfected with 
Cav!1 and Cav#2-SE-K161Q constructs showed an evident decrease of Cav!1 
protein levels upon serum removal. Similarly but to a lesser extent, cotransfection 
of Cav!1 with Cav#2-SE-K149Q in serum-free condition showed a lower decrease 
of the Cav!1 levels when compared to serum conditions (Figure 30C). These 
results resemble the decrease of Cav!1 protein levels seen when Cav#2-WT was 
used (Figure 30B). No difference was found instead with Cav!2-SE-K141Q mutant 
both in serum-free and serum-containing medium (Figure 30C), similarly to the 
Cav!1 levels when Cav!2-SE was used (Figure 30A). To confirm that any of the 
point-mutation introduced wouldn’t affect Cav#2 protein stability, same protein 
samples described above were subjected to western blotting analysis for total 
Cav#2 (Figure 31).  
These data suggest that K161 is the main aminoacid responsible for Cav#2  C-
terminal tail binding to the TID and its mutation is sufficient for determining the 
loss of the protective effect that the Cav#2-SE phosphomimetic-mutant has on 
Cav!1 protein stability. 
Surprisingly, no differences in Cav!1 protein levels alteration were found when 
cells were cotransfected with Cav!1 together with each Cav#2-WT control (Cav#2-
K141Q, Cav#2-K149Q or Cav#2-K161Q) (Figure 30D). 
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Figure 30. Investigation of the interaction of Akt-phosphorylated tail (-) with accessible neutral charged aminoacids 
(Q). A) and B) Control western blot analysis in 293T cells cotransfected with Cav! 1 and Cav#2 –SE (A) or #2 –wt for 
monitoring Cav!1 protein levels (n=2 for each condition) in presence or absence of serum. C) and D) Western blot 
analysis in 293T cells cotransfected with either #2 –SE (C) or #2 -wt mutants (D) for monitoring Cav!1 protein levels 
(n=2 for each condition). Protein levels were normalized to GAPDH. 
 
These data show that mutation K161Q in Cav#2-WT prevent the loss of Cav!1 
protein stability, suggesting an acquired protein-to-protein interaction mechanism. 
No additional effect was found with double mutation Cav#2-K149-161Q or Cav#2-
SE-K149-161Q (Figure 31). 
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Figure 31. No alteration in Cav#2 protein stability with any of the point-mutation introduced. Western blot analysis in 
293T cells cotransfected with either Cav#2–SE (A) or Cav#2-wt mutants (B) for monitoring Cav#2 protein levels (n=2 for 
each condition). Protein levels were normalized to GAPDH. 
 
To further understand the importance of the interaction with Akt-phosphorylated 
tail, changes in cellular calcium flux were measured as previously described (Figure 
32). Interestingly, similar to the control condition (Cav!1 + Cav#2), cotransfection 
of cells with each of the phosphomimetic mutant (Cav#2-SE-K149Q, Cav#2-SE-
K161Q, or Cav#2-SE-K149-161Q) resulted with a significant calcium flux 
reduction upon serum removal (!30% ,***, p<0.001) (Figure 32A). On the other 
hand, a significant increase of calcium flux (!29%,***, p<0.01) was found when 
cells were cotransfected with each Cav#2-WT control (Cav#2-K141Q, Cav#2-
K149Q, Cav#2-K161Q, Cav#2-K149-161Q) (Figure 32B).  
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Figure 32. Fluorescent-based calcium assay for analyzing changes in intracellular calcium flux in cells cotransfected 
with A) each phosphomimetic mutant (Cav#2-SE-K141Q, Cav#2-SE-K149Q, Cav#2-SE-K161Q, Cav#2-SE-K149-161Q) 
and each (B) Cav#2-WT control (Cav#2-K141Q, Cav#2-K149Q, Cav#2-K161Q, Cav#2-K149-161Q) together with 
plasmids encoding Cav!1 + Cav#2 cultivated for 48 h in presence or absence of 10% FBS. (***, p< 0.001 compared with 
Cav!2 w/o serum condition; ANOVA). Error bars show SEM. BayK8644 (1 %M) was used for LTCC activation. Here a 
representative experiment is shown (n=4). Error bars show SEM. 
 
These data confirm the western blot analysis and reveal the importance of these 
Lysines for the interaction with the Akt-phosphorylated C-terminal tail. In 
particular, these results show that neutralizing the charge of these Lysines is 
sufficient for abolishing the Cav!2-SE protective phenotype.   
 
To better understand the interaction among Akt-phosphorylated tail and site-
specific mutagenesis of K161Q in the TID, data were confirmed with a Y2H 
assay. Indeed, no interaction was found when retransformation of yeast cells was 
performed with the CaV!2-SE bait and Mouse CaV!2-K161Q TID. On the other 
hand, a strong binding was obtained when the same prey was cotransformed with 
CaV!2-WT bait (Figure 33). This evidence corroborated the presence of a 
mechanism of action that rely on Akt-dependent phosphorylation. 
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Figure 33. Confirmation of a mechanism of action that rely on Akt-dependent phosphorylation. The interaction of the 
mouse prey CaV!2-K161Q with CaV!2-WT bait after cotransformation is shown. No colonies were obtained when the 
same prey were cotransformed with CaV#2-SE bait. 
 
In conclusion, the K161Q mutation might modify the structure of the CaV#2 
subunit and/or abolish the interaction with the Akt-dependent phosphorylated 
CaV#2 C-terminal tail. This might contribute to loss of the protective effect of the 
CaV#2-SE mutant in supporting Cav!1 stability in serum-free conditions.  
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4. DISCUSSION 
 
This study reveals a mechanism through which the insulin IGF1/PI3K/PDK1/Akt 
pathway can sustain Ca
2+
 entry in cardiac cells via the LTCC and eventually 
modulate cardiac contractility. In particular, we demonstrated that the protein 
stability of the LTCC pore subunit (Cav"1) can be modulated by the Akt kinase. 
Phosphorylation of the C-terminal coiled coil of the Cav!2 chaperone subunit 
enhances LTCC protein stability by prevention of PEST-mediated Cav"1 
degradation. This Akt-dependent protective effect on Cav"1 stability relays on 
Cav!2 structural rearrangements led by an intra-molecular fold-back of the 
phosphorylated C-terminal coiled coil on its globular domain. Therefore, it is 
tempting to speculate that the Akt-mediated phosphorylation of Cav!2 and the 
consequent direct association of the Cav!2 C-terminal tail with the globular 
domain of the Cav!2 at a region we named “Tail Interacting Domain” (TID) may 
induce LTCC conformational changes that prevent PEST sequences from being 
recognized by the cell degradation system (Figure 34). Nevertheless, one cannot 
exclude the possibility that phosphorylated Cav!2 might also act indirectly through 
other, as of yet unknown, LTCC protein partners.  
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Figure 34. Proposed mechanism. Akt., followed by PDK1 activation, phosphorylates Cav!2 at the C-terminal coiled-coil 
domain. The phosphorylation allows association of the C-terminal portion of Cav!2 with the globular domain of the Cav!2 at 
a region we named “Tail Interacting Domain” (TID) (Left). In turn, a conformational shift prevents PEST sequence 
recognition, stabilizing Cav"1 protein levels. The blue and red ribbons in Cav"1 represent AID and PEST sequences, 
respectively. 
 
Several findings have shown the importance of the insulin IGF1/PI3K/Akt 
pathway in heart function. It has been previously demonstrated that 
overexpression of an active form of Akt1 results in improved cardiac inotropism 
both in vivo [15] and in vitro [47], augmenting ICa,L. Similar results were obtained 
in a mouse model with cardiac specific Akt1 nuclear-overexpression [48] and in 
mice deficient for PTEN, an antagonizer of PI3K activity [49]. In addition, short-
term administration of IGF1 in animal studies has also been reported to increase 
cardiac contractility [25]. However, the mechanism through which the insulin 
IGF1/PI3K/Akt pathway affects Ca
2+
 current has remained elusive. In an elegant 
in vitro study, Viard and coworkers [105] demonstrated that a region of the Cav!2a 
subunit is involved in the PI3K-induced chaperoning of Cav2.2a in neurons. This 
PI3K-induced regulation was shown to be mediated by Akt phosphorylation of the 
Cav!2a subunit, which in turn regulates Cav2.2a trafficking from the ER to the 
plasma membrane. Notably, the C-terminal region containing the putative Akt-
phosphorylation consensus site is conserved in all variants of the Cav!2 subunit 
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both in neurons and heart [105], thus illustrating the importance of this site. In 
addition, strong conservation was found also among the TID region of all Cav! 
isoforms including also the Lysines (underlined in the Figure 35) determinant for 
the binding with the Akt-phosphorylated C-terminal region (Figure 35): 
 
Cav"1119 VPVQGVAITFEPKDFLHIKEKYNNDWWIGRLVKEGCEVGFIPSPVKLDSLRLLQEQKL 
Cav"2129 VPVPGMAISFEAKDFLHVKEKFNNDWWIGRLVKEGCEIGFIPSPVKLENMRLQHEQRA 
Cav"378  CPVQGSGVNFEAKDFLHIKEKYSNDWWIGRLVKEGGDIAFIPSPQRLESIRLKQEQKA 
Cav"4109 VPVPSTAISFDAKDFLHIKEKYNNDWWIGRLVKEGCEIGFIPSPLRLENIRIQQEQ-- 
          **      *  ***** ***  ************    *****  *   * * **  
 
Figure 35. Homology alignement of Cav!2-TID with mouse Cav! subunits. Conserved residues are shown in grey boxes. 
Blast analysis revealed that Cav!1 shows 83.9%, Cav!3 77.4%, Cav!4 90.3% of identity in the 31 residues overlap with 
Cav!2-TID (yellow box), respectively. 
 
Interestingly, two very short human cardiac splice isoforms, Cav!2f and Cav!2g 
with preserved Akt-site have been shown to be essential for modulating Ca
2+
 
channel function and Cav"1 channel density [74, 114].  Strikingly, the same two 
Cav!2 variants do not contain the protein kinase PKA phosphorylation site [115], 
consistent with our data suggesting no PKA involvement in the modulation of 
LTCC density (data not shown). In line with our hypothesis, also the TID-site has 
been found conserved in the short Cav!2f isoform. As corollary, the presence of 
conserved C-terminal region and TID in all Cav!2 splice isoforms corroborates the 
relevance of identifying new functional motifs that may give important insights 
into LTCC modulation. All together, these evidences support the notion that the 
C-terminal region of Cav!2 might be a potential pharmacological target.  In line 
with this, we showed that Akt-phosphomimetic sequences belonging to the C-
terminal region of Cav!2 are determinant for a positive effect in the control of 
LTCC density by maintaining Cav"1 protein stability and function. However, we 
couldn’t exclude the possibility that Akt-dependent phosphorylation of CaV!2  
might also act indirectly through other LTCC protein partners, being a trigger for 
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the recruitment of other proteins involved in Cav"1 protein stability modification.  
Nevertheless, using a yeast two-hybrid system approach, we showed that only the 
Akt-phosphorylated Cav!2 and not the Cav!2-WT C-terminal interacts with the 
globular domain of the Cav!2 at the “tail interaction domain” (TID), thus 
providing the proof of concept for a mechanism of action that relies on Akt-
dependent phosphorylation. This corroborates the idea that the protective action of 
Akt-phosphomimetic sequences on Cav!2 might occur through the direct 
interaction to the Cav!2 TID. Notably, K161 was identified as the relevant 
aminoacid responsible for this interaction. Indeed, our data suggest that mutation 
of K161 is sufficient to abolish the interaction of the Akt-dependent 
phosphorylated CaV!2 C-terminal tail (Figure 33-36) with the TID.  
 
 
Figure 36. Proposed mechanism. K161 was identified as the relevant aminoacid responsible for this interaction. 
 
Therefore, it is tempting to speculate that, when Akt is not phosphorylated, the 
alternate conformational status of the globular CaV!2  determines a different 
interaction between Cav"1 and Cav!2 subunits, that results with Cav"1 PEST 
sequences recognition by the cell degradation machinery. 
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In conclusion, results from this doctoral thesis led to further insights into the role 
of the insulin IGF1/Akt signaling pathway and its role in the modulation of 
myocardial physiology and HF. In fact, the re-establisment of cardiac function in 
HF could be obtained by finding a new equilibrium of this signaling pathway that 
favor physiological rather than pathological cardiac hypertrophy. This can be 
reached by acting on downstream targets modulated by the Akt kinase, in 
particular by positively affecting cardiac function through the modulation of 
myocardial Ca
2+
 handling. Notably, it has been demonstrated that diabetes and 
DCM are associated with impaired activation of the Akt signaling pathway [116, 
117], while its reactivation has been shown to promote CMC survival, improving 
Ca
2+
 handling and contractile function [15]. Also alterations in the density or 
function of L-type calcium channels (LTCCs) have been related to a variety of 
cardiovascular diseases, including atrial fibrillation, heart failure, and DCM [58, 
88, 89]. Therefore, unraveling the functional role of potential Akt-
phosphomimetics Cav!2 sequences might be of relevance for the development of 
therapeutic tools for the treatment of HF that could increase or reestablish a 
“correct” cardiac inotropism by increasing the number of functional LTCC in 
diseased CMCs. In addition, the high level of conservation of PEST sequences in 
the Cav"1 subunit throughout evolution (Table 5), the high homology of TID in all 
mouse Cav! subunits and the Akt-consensus site conserved in all variants of Cav!2 
subunit indicate that our proposed mechanism may play a universal role in 
regulating cell Ca
2+
 handling and survival.  
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